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 General Introduction 11
1.1 Metabolic syndrome
1.1.1 Definition
Overweight and obesity is rapidly becoming a major health problem, momentarily affecting 
more than 1 billion adults, and over 300 million of them clinically obese. It is predicted by 
the World Health Organization (WHO) that by 2015, approximately 2.3 billion adults will be 
overweight and more than 700 million will be obese.1 This overweight/obesity pandemic is 
not only restricted to adults, but childhood obesity is already epidemic in some regions. It 
is estimated that around 10% of the youths are obese worldwide.  Overweight and obesity 
lead to adverse metabolic effects on blood pressure, lipid metabolism and insulin resis-
tance. This clustering of pathologies is called as the metabolic syndrome (MetS) and has 
also started to emerge in children at young ages, a phenomenon that was inconceivable a 
few decades ago.
The MetS is also known syndrome X, Reaven’s syndrome and insulin resistance syndrome. 
The latter and MetS are now commonly and interchangeably used names. MetS was first 
described in early 1920s by Kylin as a constellation of hypertension, hyperglycaemia and 
gout.2 Over the years, different criteria were used to define the MetS. In late 1940s the MetS 
was redefined by Vague in which android or male-type obesity was included.3 In 1988 Reaven 
stated the clinical importance of the MetS. In the landmark publication of his 1988 Banting 
Medal award lecture, Reaven described syndrome X as a constellation of insulin resistance, 
hyperglycaemia, hypertension, low high-density lipoprotein cholesterol (HDL-C) levels and 
increased very low-density lipoprotein (VLDL)-triglyceride levels.4 In 1999, World Health 
organisation (WHO) has attempted to create an international unifying guideline.5 However, 
the numbers of metabolic disorders that are associated with the MetS has increased in the 
last few years. Therefore, different expert groups (the European Group for the Study of Insu-
lin Resistance (EGIR), the International Diabetes Federation (IDF) and the Third Report of the 
National Cholesterol Education Program’s Adult Treatment Panel (NCEP ATP III) redefined 
the MetS and modified the WHO definition (Table 1).6-9 Nowadays, the WHO and NCEP ATP III 
definitions are most commonly used. The exact pathogenesis of the MetS is not clear. It is 
suggested that MetS is the result of increasingly sedentary lifestyles combined with ready 
access to energy-rich food sources in genetically susceptible individuals. Subjects with the 
MetS have high risk for developing insulin resistance and cardiovascular diseases.








Table 1 The different definitions of the Metabolic Syndrome
Major criteria Minor criteria









BMI > 30 kg/m2
and/or
waist/hip ratio
>0.9 (♂) or 
>0.85 (♀)
dylipidemia
HDL-C < 0.9 (♂) 
or < 1.0 mM ♀
TG ≥ 1.7 mM
hypertension





> 20 µg/min 
or albumin/












HDL-C < 1.0 mM
TG > 2.0 mM
hypertension










or 88 cm (♀)
low HDL-C
< 1.03 mM (♂)











< 1.03 mM (♂)
< 1.29 mM (♀)
or treatment for 
this abnormality
triglycerides
≥ 1.7 mM or 




≥130 mm Hg, 
diastolic BP 







HDL-C: high density lipoprotein-cholesterol
TG: triglyceride
BP: blood pressure
FPG: fasting plasma glucoses
EGIR: European Group for the Study of Insulin Resistance, IDF: International Diabetes Federation, NCEP 
ATP III: Third Report of the National Cholesterol Education Program’s Adult Treatment Panel, HDL-C: high 
density lipoprotein-cholesterol, TG: triglyceride, BP: blood pressure, FPG: fasting plasma glucoses.
1.1.2 Prevalence and clinical consequences
The worldwide prevalence of MetS is not exactly known, because of different definitions are 
being used. Therefore comparisons in the prevalence are difficult to make. However, most 
studies do agree that the prevalence is rapidly increasing. Particular alarming is the increase 
in children. Consistent observations are that the prevalence is age-dependent and with a high 
ethnic variation. In the United States almost 25% of the total population has the MetS accord-
ing to the NCEP ATP III definition.10 In Europe the prevalence of the MetS varies between 24.5% 
in Greece and 32.6% in Spain.11,12 In Asia, the prevalence is less than 20%.13,14
The most important clinical consequences of MetS are the insulin resistance and the car-
diovascular diseases. MetS increases the risk for type 2 diabetes mellitus independent of 
insulin resistance.15 Moreover, the MetS is associated with an increased risk for cardiovas-
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cular mortality and morbidity.16-18 Subjects with MetS have 3 times higher risk for dying of 
cardiovascular heart diseases when compared with subjects without MetS. MetS is also 
associated with chronic kidney diseases independent of the presence of type 2 diabetes 
mellitus or hypertension, although the underlying mechanism is not known.19,20 Simultane-
ous occurrence of both metabolic syndrome and insulin resistance worsens the risk for 
cardiovascular diseases. Taken together, the MetS has major clinical impacts.
1.1.3 Insulin resistance
Under normal physiological conditions, ingested glucose is taken up and stored in the liver 
and in insulin-sensitive peripheral tissues (predominantly the skeletal muscle and the adi-
pose tissue). Plasma glucose stimulates the production and secretion of insulin by the pan-
creatic insulin producing β-cells. On the one hand, insulin inhibits hepatic glucose production 
by inhibiting the glycogenolysis and gluconeogenesis. On the other, insulin stimulates the 
uptake of glucose and the formation of glycogen in the skeletal muscle. Furthermore, insu-
lin inhibits the production of lipoprotein particles and energy substrates such as lactate 
and free fatty acids (FFAs) in the liver and the adipose tissue. In the adipose tissue, insulin 
also promotes the synthesis of triglycerides (TG) as energy storage and inhibits lipolysis. 
In obese state, energy intake exceeds the capacity to store energy in the adipose tissue 
leading to energy ‘overflow’ to ectopic sites. These ectopic sites are observed in the liver, 
skeletal muscle and pancreatic insulin-secreting β-cells.21,22 The liver plays a pivotal role 
in maintaining the glucose and lipid metabolism. Several clinical studies have shown that 
lipid accumulation in the liver is associated with insulin resistance.23 Patients with type 2 
diabetes mellitus have a defect glucose metabolism in the liver and skeletal muscles.24,25
Under insulin resistance conditions, insulin fails to suppress the production of glucose and 
energy substrates, to stimulate the glucose uptake, and to inhibit lipolysis. Therefore, Insu-
lin resistance is defined as a state of reduced responsiveness to normal circulating insulin 
levels affecting multiple organs.
Insulin resistance is a key component in the pathogenesis of the metabolic syndrome and 
type 2 diabetes mellitus. Numerous studies have shown that obesity and overweight are the 
major contributors of the metabolic syndrome. It is agreed that impaired glucose metab-
olism, exacerbate lipid accumulation and inflammatory processes contribute to insulin 
resistance. The pathogenesis of insulin resistance has been studied extensively; much is 
still to do since the incidence of insulin resistance has become epidemic.








1.2 PAI-1 and insulin resistance
Several epidemiological studies have shown association between increased plasma PAI-1 
levels and body mass index, triglyceride levels and insulin resistance.26-29 In the Insu-
lin Resistance Atherosclerosis Study (IRAS) plasma PAI-1 levels predict the development 
of diabetes independently from other known risk factors.26 Progression of PAI-1 plasma 
levels in addition to initial high plasma levels are associated with the incident diabetes.30 
Improving insulin resistance by diet, exercise or oral antidiabetic drug treatment results 
in decreased plasma levels of PAI-1 antigen and activity.31-34 Although, PAI-1 is known to be 
synthesized by various tissues including liver and adipose tissue, the source and the mech-
anism of increased plasma PAI-1 levels in obesity and insulin resistance are incompletely 
understood. Increased plasma PAI-1 in obesity might be derived from the adipose tissue. 
Alternatively, increased plasma PAI-1 can be the result of local and systemic production 
following stimulation by adipokines.
The expression of PAI-1 in adipose tissues is positively correlated with obesity in human and 
rodents, suggesting a possible role in the development of obesity and insulin resistance.35-39 
This is supported by the observation made in genetically obese and insulin resistant mouse 
models. Disruption of the PAI-1 gene in ob/ob mice reduces adiposity and improves the met-
abolic profile determined by glucose and insulin tolerance test.40 Two other studies showed 
that mice lacking PAI-1 do not develop diet-induced obesity and insulin resistance.41,42 
Downregulation of PAI-1 by angiotensin type I receptor antagonist in wild-type (WT) mice 
ameliorates diet-induced obesity, hyperglycemia and hyperinsulinemia. Administration of 
synthetic PAI-1 inhibitor induces higher insulin sensitivity in WT mice.43These studies sug-
gest that PAI-1 may not merely increase in response to obesity and insulin resistance, but 
may have direct causal role in the development of obesity and insulin resistance. In contrast 
to these studies, PAI-1 deficient mice kept on a high fat diet for 3-8 weeks develop more 
adipose tissue.44 In agreement with this, transgenic mice overexpressing PAI-1 have lower 
body weight, lower adipose tissue mass and less intraperitoneal fat.45
Taken together, although strong clinical evidence is present that PAI-1 plays an important 
role in insulin resistance and obesity, it is not clearly confirmed yet by experimental studies 
how enhanced PAI-1 is linked to the pathological conditions of insulin resistance and obe-
sity. Does PAI-1 contribute to the pathogenesis of insulin resistance and obesity? Or is PAI-1 
merely an epiphenomenon of insulin resistance and obesity?
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1.3 Atherosclerosis
Cardiovascular disease (CVD) includes myocardial infarction, congestive heart failure, 
stroke and peripheral artery diseases. CVD is the leading cause of all mortality and mor-
bidity worldwide. In North America more than 1 out the 3 persons will die of CVD and it is 
predicted that health costs will exceed 430 billion dollars.46 Comparable mortality numbers 
hold true for The Netherlands. Atherosclerosis is the primary cause of CVD. Atheroscle-
rosis is a progressive disease of the vessel wall that already begins in young adults. The 
disease primarily occurs in the large and medium-sized elastic and muscular arteries. The 
aetiology is very complex and it involves genetic, environmental factors and the interaction 
between these factors. Among the risk factors are diabetes mellitus, dyslipidemia, smok-
ing, hypertension, gender, age and physical activity. Thus, atherosclerosis results from the 
combination of genetic susceptibility and unhealthy environmental influences.
1.3.1 Pathogenesis of atherosclerosis
Although the knowledge of atherosclerosis has expanded in the last decades, the exact 
mechanism underlying the pathogenesis is still not fully understood. The traditional view 
of the pathogenesis of atherosclerosis is the imbalance between cholesterol deposition 
and removal in the subendothelial layer after injury to the endothelium.47 The accumula-
tion of cholesterol can be facilitated by increased plasma LDL cholesterol levels leading 
to proliferation of smooth muscle cells (SMC). In the subendothelial layer, LDL cholesterol 
can be modified and subsequently engorged by resident macrophages to form foam cells 
(Figure 1). These foam cells form the initial fatty streak lesions which precede the forma-
tion of complex fibrous lesions.
The current concept involves inflammation and atherosclerosis is now also considered as 
an inflammatory disease of the large and medium-sized arteries. Inflammatory processes 
are present in all stages of atherosclerosis progression (Figure 1). Triggers of atheroscle-
rosis, such as modified LDL can stimulate endothelial cells to produce an array of inflam-
matory proteins including chemotactic factors like monocyte chemoattractant protein-1 
(MCP-1), growth factors such as macrophage colony-stimulating factor (M-CSF) and adhe-
sion molecules. Among the adhesion molecules are vascular cell adhesion molecule-1 
(VCAM-1), intracellular cell adhesion molecule-1 (ICAM), P-selectin and E-selectin. These 
adhesion molecules and chemotactic factors attract monocytes and T cells into the sub-
endothelial layer initiating the formation of the early atherosclerotic plaque. The prolifera-
tion and differentiation of the attracted monocytes are then stimulated by M-CSF. These 
attracted monocytes and T cells on their turn can release inflammatory cytokines, such as 
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) that further amplify the inflam-








matory activity in the vessel wall. As the atherosclerotic lesion progresses, macrophages 
and T cells stimulate the migration of smooth muscle cells (SMC) into the intima and the 
production of collagen. A fibrous cap is then formed together with extracellular lipid depos-
its, SMC-derived extracelluar matrix, and often with necrosis. A complex atherosclerotic 
lesion is then a fact. Such a complex lesion can rupture depending on the composition and 
vulnerability. Vulnerable plaques usually have thin fibrous caps and increased number of 
inflammatory cells. The fibrous cap reflects the balance between matrix production by SMC 
and degradation by matrix metalloproteinases. Calcification and neovascularisation can 
also influence the stability of the atherosclerotic plaque.  In addition, thrombogenicity of a 
lesion depends on the presence of proteins of the coagulation cascade such as tissue factor 
and plasminogen activators. Usually a plaque ruptures at the edges of the lesion leading to 
















Progression of the atherosclerotic process
Figure 1: Atherosclerotic process 
Figure 1 Atherosclerotic process
In the early atherosclerotic process monocytes adhere, migrate, take up modified LDL and differentiate into 
macrophage foam cells. The macrophage foam cells produce and release cytokines attracting even more 
inflammatory cells, such as T cells.  In the advance process, smooth muscle cells migrate and proliferate to 
form fibrous cap overlying a poll of lipid-laden macrophages, T cells, necrosis, and cholesterol crystals. EC: 
endothelial cells, LDL: low-density lipoprotein, SMC: smooth muscle cells
1.3.2 Inflammation and atherosclerosis
As discussed above (section pathogenesis of atherosclerosis) inflammatory processes play 
a key role in the development of atherosclerosis. The nuclear factor κB (NF-κB) is a cen-
tral regulatory factor of the inflammatory processes. NF-κB is considered to play a crucial 
role atherosclerosis locally at the vessel wall. Many inducers and target genes of NF-κB are 
implicated to be involved throughout the atherosclerotic process.48 In the initial phase NF-κB 
can be activated in the endothelium by atherosclerogenetic stimuli such as modified LDL and 
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inflammatory cytokines produced at the lesion site. Additionally, NF-κB is demonstrated to be 
involved in the regulation of the modification of LDL, the expression chemokines and adhe-
sion molecules.49-56 All are important in the initial phase of the atherosclerotic process. In the 
advanced lesions NF-κB plays an important role in SMC migration and proliferation. The sta-
bility of an atherosclerotic plaque may also be governed by NF-κB by controlling apoptosis and 
necrosis. Macrophage-specific deletion of the main NF-κB activator IKK2 results in athero-
sclerotic lesions with increased necrosis and apoptosis.57 However, reduced activity of NF-κB 
not only results in increased cell death, but also in reduced secretion of the anti-inflammatory 
cytokine IL-10. In the same setting reduced secretion of the pro-inflammatory cytokine TNF-α 
is also observed. In line with these findings, mice with p50 deficiency in the hematopoietic 
system show reduce less atherosclerosis, but more inflammation in the lesions.58 Thus, this 
emphasizes that NF-κB as the central regulatory factor of inflammation has a complex role 
by influencing both pro-atherogenic and anti-atherogenic process in the vessel wall. There-
fore, much is still to do to disentangle how the NF-κB activation and signalling pathways are 
orchestrated during the development of atherosclerosis.
In contrast, not many studies have been performed to investigate the underlying mechanisms 
of systemic inflammation on the development of atherosclerosis. Countless epidemiologic 
studies have shown that low-grade systemic inflammation is associated with metabolic syn-
drome. The liver is the key regulatory organ in the systemic inflammatory processes. The 
production of acute phase proteins, like C-reactive protein (CRP), serum amyloid A (SAA), 
plasminogen activator inhibitor-1 (PAI-1) are most relevant in this respect. CRP and PAI-1 
are increased in subjects with the metabolic syndrome. PAI-1 has been shown to increase 
the risk of atherothrombotic events and may also promote the progression of atheroscle-
rosis.59 Experimental studies have demonstrated that CRP can activate endothelial cells to 
produce inflammatory markers. Furthermore, SAA can stimulate the cholesterol uptake 
by smooth muscle cells in an atherosclerotic plaque.60 Therefore, hepatic inflammatory 
parameters are considered to be strongly associated with atherosclerosis and cardiovas-
cular diseases. However, the exact mechanism by with systemic inflammation affects the 
development of atherosclerosis at the vessel wall has not been identified.
1.3.3 Endothelial progenitor cells and atherosclerosis
The first manifestation of atherosclerosis is the development of endothelial dysfunction, 
which is characterized by an activation of endothelial cells (EC) and decreased nitric oxide 
availability and deterioration of the endothelial monolayer. The initial damage is revers-
ible. However, when no sufficient repair mechanism is present, ongoing deterioration of the 
endothelial monolayer can lead to the development of atherosclerotic lesions. The underly-
ing molecular mechanism of endothelial repair is not fully understood.








A population of pluripotent cells within the peripheral blood has been described that are 
capable to differentiate into endothelial cells.61 These endothelial progenitor cells (EPC) 
are able to home to sites of injury in the vascular endothelium and subsequently enhance 
neoangiogenesis after tissue ischemia. Therefore, the concept rose that EPC are recruited 
from the bone marrow to sites of damaged endothelium, where they can home and differen-
tiated into mature endothelium cells (Figure 2). The phenotypic and functional characteris-
tics of EPC are divergent. The widely accepted consensus defines cells positive for surface 























Figure 2 Recruitment, homing and differentiation of an endothelial progenitor cell
The endothelial progenitor cell recruited via vascular endothelial growth factor and homes to the site 
of injury where it differentiates into an endothelial cell. There it forms a new endothelial layer. EPC: 
endothelial progenitor cell, VEGF: vascular endothelial growth factor, VEGFR-2: vascular endothelial growth 
factor receptor-2. (courtesy of prof. dr. A.J. van Zonneveld)
The number and the functional activity of circulating EPC are correlated with cardiovascu-
lar risks. The EPC levels and the proliferation and migration activity are reduced in patients 
with CVD, diabetes or hypercholesterolemia.62-65 Other cardiovascular risk factors such 
as smoking and CRP are also associated with impaired EPC numbers and function. In the 
atherosclerotic apoE-/- mouse model systemic transfusion of systemic progenitor cells 
inhibits the progression of atherosclerotic lesions.66
It is apparent that EPC can facilitate endothelial repair and is involved in the development 
of atherosclerosis. However, it is not clear what the exact contribution of EPC is in cardio-
vascular diseases.
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1.4 Lipid metabolism
Cholesterol and triglycerides are of essential for many different processes in the human 
body and for energy storage. Since cholesterol and triglycerides are hydrophobic, they are 
packed into lipoproteins particles for transport in the circulation. Dietary cholesterol and 
triglycerides are absorbed by the intestines and packed into chylomicrons containing mainly 
triglyceride (Figure 3). Subsequently, these chylomicrons are secreted in the circulations 
where they acquire apolipoproteins. Once in the circulation, chylomicrons are subjected to 
lipolysis by endothelium-bound lipoprotein lipase (LPL) resulting in the generation in fatty 
acid that enters the peripheral tissues for energy storage or source. The chylomicron- rem-
nant particles are further hydrolysed by hepatic lipase (HL) and subsequently taken up by 
the liver via the low-density lipoprotein receptor (LDLR) or the LDLR-related protein (LRP). 
The liver plays a central role in the lipid metabolism.  The liver processes the cholesterol 
and triglycerides and secretes these again into the circulation packed into very low-density 
lipoprotein (VLDL) particles where they acquire apolipoproteins. Similar to chylomicrons, 
VLDL particles are hydrolysed by LPL and eventually resulting in low-density lipoprotein 
(LDL) particles. LDL in its turn can be taken up the liver via the LDLR for further process-
ing. LPL is synthesized and secreted by parenchymal cells throughout the body. The activity 
of LPL is influenced by several apolipoproteins. Apolipoprotein CII serves as a co-factor, 





















Figure 3 Lipid metabolism
See text for explanation. TG: triglyceride, FFA: free fatty acid, LPL: lipoprotein lipase, LDLR: low-density 
lipoprotein receptor, LRP: low-lipoprotein receptor-related protein, VLDL: very low-density lipoprotein 
receptor








Originally identified as a member of the LDLR gene family, LRP was suggested to play role 
in lipid metabolism. In vitro studies showed that LRP serves as a receptor for apoE-rich 
chylomicron remnants and lipoprotein lipases.71,72
1.4.1 Low-density lipoprotein receptor-related protein
Structure and expression
The low-density lipoprotein receptor-related protein (LRP) gene is located on chromosome 
12 and was identified in 1988 by Herz J et al.73 It is also known as α2-macroglobulin recep-
tor, LRP1 and CD91.74 LRP consists of 4544 amino acids and is synthesised as a large 600 
kDa single polypeptide chain in the endoplasmatic reticulum, which is than cleaved into a 
515 kDa and an 85 kDa subunit by furin in the Golgi apparatus. Both subunits remain non-
covalently associated where the 515 kDa subunit binds ligands and the 85 kDa subunit is 
anchored in the plasma membrane. The endoplasmatic reticulum-resident chaperone pro-
tein, the 39 kDa receptor- associated protein (RAP) ensures the correct trafficking of LRP 
along the secretory pathway.75 Thereby, RAP also promotes proper optimal folding of LRP 
and prevents premature intracellular binding to its ligands.
LRP is a member of the big low-density lipoprotein (LDL) receptor (LDLR) gene family. This 
family also includes the LDLR, very low-density lipoprotein (VLDL) receptor (VLDLR), apoli-
poprotein E receptor 2 (ApoE-R2) and megalin/LRP2/glycoprotein 330 (Figure 4). As other 
members of the LDL receptor gene family LRP contains structural domains that include: a) 
ligand-binding cysteine-rich complement-type repeats, b) epidermal growth factor (EGF) 
receptor-like cysteine-rich repeats, c) b-motifs with YWTD repeats, d) transmembrane 
domain and e) a cytoplasmatic domain that harbours 1-3 NPxY motifs (Figure 4).73  The 
ligand-binding complement-type repeats are arranged in four different clusters (cluster I, 
II, III and IV) containing 2, 8, 10 and 11 repeats, respectively. Cluster II and IV bind most of the 
known ligands. A common feature of most the LDLR gene family members is their ability to 
bind RAP. RAP antagonizes ligand binding to all members of the LDLR gene family. There-
fore, extracellular recombinant RAP is extensively exploited as a tool to study the biology of 
the LDLR gene family.
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ligand binding complement type repeats
β-motifs with YWTD repeats
EGF receptor-like repeat
transmembrane domain
cytoplasmatic domain with NPxY motif
Figure 4 The low-density lipoprotein receptor gene family
The LDL receptor gene family consists of several homologous transmembrane receptors involved in 
endocytosis. All members of the LDL receptor gene family are composed of the same protein domains with 
similar topological organisations. LDL receptor gene family member include the low-density lipoprotein 
receptor-related protein (LRP), megalin (pg330 and LRP2), the apolipoprotein E receptor-2 (apoE-R2), the 
very low-density lipoprotein receptor (VLDLR), and the low-density lipoprotein receptor (LDLR).
LRP is widely expressed in a large variety of tissues. It is abundantly present in the liver, 
brain, lung, spleen, intestines, reproductive tract and fat tissue.76  Furthermore, LRP is also 
expressed in a spectrum of diverse cell types, such as smooth muscle cells, macrophages 
and fibroblast.
Physiological functions
LRP is a multi-ligand protein. To date, LRP is known to recognise over 50 functionally and 
structurally numerous ligands (Table 2).77,78 Originally LRP was identified as lipid metabo-
lism receptor. Additionally, LRP is shown to serve as a regulator of the extracellular pro-
teolytic activity by rapid internalising of the uPA/PAI-1 complex in concert with the uPAR 
and modulating the matrix metalloproteinase levels.79-82 These evidences imply that LRP is 
a multifunctional scavenger receptor. Different mice studies confirmed that LRP is indeed 








an endocytic scavenger receptor that is not only involved in the lipid metabolism, but also in 
haemostasis metabolism.83-85
Targeted deletion of the LRP gene revealed that LRP is absolutely required in the early 
embryonic development, suggesting that its physiological role is not restricted as a cargo 
transporter of extracelluar proteins.79 The exact mechanism of embryonic lethality is 
unclear. However, LRP is now known also to be involved in intracellular signalling. It is 
thought that the cytoplasmatic tail with the NPxY motifs are involved in the interaction with 
numerous intracellular proteins of the signal transduction pathways.86 Most of these pro-
teins are adaptor proteins in the regulation of cell signalling, migration and proliferation. 
Depending on the phosphorylation state of LRP can regulate various intracellular signals 
in response to different extracellular stimuli by modifying its association with adaptor 
proteins.87 LRP is shown to control cell migration and proliferation by phoshorylation in 
response to PDGF-BB in vascular SMC (VSMC). Failing to control the PDGF signalling in the 
SMC results in increased atherosclerosis (see section LRP and atherosclerosis).88
1.4.2 LRP and atherosclerosis
As abovementioned, conventional LRP knockout mice are not viable and die on day 10 of 
gestation. Therefore, tissue-specific disruption of LRP using the Cre/loxP recombination 
system has been generated to study the physiological of LRP in vivo. Inactivation of hepatic 
LRP in LDLR deficient mice (MX1Cre LRPflox/flox) results in the accumulation of cholesterol-
rich remnants lipoproteins suggesting an atherogenic lipid profile.85 Independent of plasma 
cholesterol levels these mice show increased atherosclerosis on an atherogenic apoE-/- 
background.89
Next to plasma lipids levels, the proliferation and differentiation of VSCM and macrophages 
are important in the development of atherosclerosis (see section atherosclerosis). LRP 
plays a pivotal role in the vascular integrity and the prevention of atherosclerosis in the 
VSMC.88 Mice lacking LRP in their VSMC have similar plasma lipid levels as mice with LRP 
present in the VSMC. However, VSMC LRP deficient mice show increased susceptibility to 
development atherosclerotic lesions. The elastic layer of the aorta is disrupted. Increase 
VSMC proliferation and aneurysm formation are observed as a result of abnormal control 
of the PDGFR expression and activation.
The role of macrophage LRP in the development of atherosclerosis is not fully known. In 
vitro studies implicate that LRP in macrophages has a pro-atherogenic potential. LRP is 
highly expressed in atherosclerotic lesions and upregulated in macrophages undergo-
ing foam cell formation.90,91 Additionally, LRP regulates ß2-integrin-mediated adhesion of 
monocytes to endothelial cells allowing monocytes to migrate into the intima and to differ-
entiate into macrophages.92 Macrophage LRP has also been demonstrated to play a role in 
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the translocation of 12/15-lipoxygenase, which stimulates the formation of oxidized LDL.93,94 
In concert with the LDLR, LRP can mediate the uptake of apoE-rich atherogenic lipoproteins 
into the macrophage.95-97 Since all these processes promote the formation of foam cells, 
one would predict that LRP promotes the development of atherosclerosis at the level of 
macrophages.
Table 2 Extracellular LRP ligands 
Lipid metabolism Growth Factors
Apo E PDGF
Chylomicron remnants Midkine
Hepatic lipase Connective tissue growth factor
Lipoprotein lipase TGF-β
Lipoprotein (a)
β-VLDL Infection and immunity
Saposin Aminoglycosides
Sphingolipid activator protein Circumsporozoite protein
Complement C3
Protease and protease/inhibitor complexes Gentamicin
Activated α2-M* HIV-Tat protein
Aprotinin Lactoferin 
C1s/C1q inhibitor Minor group rhinovirus
Elastsae/α1-anti-trypsin Polymyxcin B
















Thrombin/anti-thrombin III Amyloid precursor protein
















1.5 Outline of this thesis
In this thesis we aimed to expand our knowledge on the pathophysiological aspects of the 
metabolic syndrome in transgenic mice. The metabolic syndrome involves multiple aspects 
and has a major impact on cardiovascular diseases. In the first part of thesis the role of 
PAI-1 in the development of insulin resistance will addressed. This part will also focus on 
the mechanism of plasma PAI-1 clearance. Plasma PAI-1 is increased in patients with the 
metabolic syndrome. Obesity and insulin resistance are key components of the metabolic 
syndrome. The increased plasma PAI-1 levels are suggested to be the result of increased 
expression in the vascular endothelium, adipose tissue and liver. However, it is not known if 
the clearance also contributes to the increased plasma PAI-1 levels.  Chapter 2 describes 
the clearance and plasma levels of PAI-1 in a genetically and a diet-induced insulin resistant 
mouse models.  A number of studies have shown that LRP can bind, internalise and degrade 
PAI-1 in vitro. However, it is not known whether LRP indeed plays a role in the clearance 
of plasma PAI-1 in vivo.  Chapter 3 addressed the role of hepatic LRP in the regulation of 
plasma PAI-1 in vivo. For this purpose, we studied the clearance of PAI-1 in hepatic LRP 
deficient mice under different conditions.
In the second part of this thesis, the roles of LRP in atherosclerosis and LPL activity in 
lipid metabolism are addressed. Hepatic LRP deficient mice have elevated fasted plasma 
cholesterol and triglyceride levels, mainly present as VLDL particles on a LDLR-/-VLDL-/- 
background. Since VLDL is continuously produced in the liver, VLDL remnants still need to 
be cleared to maintain a steady state level.   Chapter 4 addressed the whether LPL activity 
is important for the hepatic clearance of VLDL remnants independent of the three major 
apoE-recognizing receptors LRP, LDLR and VLDLR.  LRP in the liver and SMC is shown to 
have atheroprotective role. Macrophages play a key role in the development of atheroscle-
rosis next to SMC. Data from several in vitro studies suggest a pro-atherogenic of LRP in the 
macrophage. In chapter 5 we investigated the role macrophage LRP in the development of 
atherosclerosis in vivo.
Finally, role of low-grade inflammation in endothelial restoration is addressed. Subjects 
with the metabolic syndrome have chronic low-grade inflammation and increased risk for 
cardiovascular diseases. Chapter 6 describes the influence of low-grade inflammation on 
the number of EPC in patients with the metabolic syndrome. The association between the 
number of EPC and the extent of atherosclerosis in the carotid artery is also described.
The results obtained from these studies and the implications for future research are dis-
cussed in chapter 7.
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Increased plasma PAI-1 levels are observed in insulin resistance human subjects. It is 
thought that increased plasma PAI-1 levels can predict the incident of insulin resistance. 
This is supported by several rodent mouse models. Mice lacking PAI-1 do not develop insu-
lin resistance. However, others showed that PAI-1-deficient mice have more adipose tissue 
and a worsened metabolic profile. Therefore, it is not fully understood how PAI-1 is involved 
in insulin resistance. In the present study we investigated 1) the plasma PAI-1 levels in 
diet-induced insulin resistant mice in time and 2) the contribution of the clearance of PAI-1 
to the increased plasma PAI-1 levels in insulin resistant mice. We found that plasma PAI-1 
levels increase in diet-induced insulin resistance and that these increased plasma PAI-1 
levels follow rather than precede insulin resistance. Insulin resistance was already present 
after 4 weeks of high fat diet, whereas increased plasma PAI-1 levels were observed only 
after 12 weeks of high fat diet. Furthermore, we showed that the clearance of PAI-1 does not 
contribute to the increased plasma PAI-1 levels in both diet-induced and genetically insulin 
resistance mice. Taken together, our data support the concept that PAI-1 is not causally 
involved in the development of insulin resistance.
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Introduction
Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of tissue-type 
plasminogen activator (t-PA). Increased plasma PAI-1 levels are associated with decreased 
fibrinolysis.1 Several epidemiological studies have shown strong association between 
increased plasma PAI-1 levels on one hand, and obesity and insulin resistance on the other.2-5 
Progression of PAI-1 plasma levels in addition to initial high plasma levels are associated with 
incident of diabetes.6 However, the exact mechanism of increased PAI-1 insulin resistance are 
incompletely understood.
The expression of PAI-1 in adipose tissues is positively correlated with obesity in human and 
rodents,7-11 suggesting a possible role in the development of obesity and insulin resistance. 
However, animal studies on the role of PAI-1 in insulin resistance show contradicting data. 
Disruption of the pai-1 gene in ob/ob mice reduces adiposity and improves the metabolic 
profile as determined by glucose and insulin tolerance test.12 Additionally, PAI-1-deficient 
mice do not develop diet-induced obesity and insulin resistance. Administration of synthetic 
PAI-1 inhibitor induces higher insulin sensitivity in WT mice.13,14 These studies suggest that 
PAI-1 may not merely increase in response to obesity and insulin resistance, but may have 
direct causal role in obesity and insulin resistance. In contrast to these studies, others 
showed that PAI-1-deficient mice develop more adipose tissue.15 In agreement with this, 
transgenic mice overexpressing PAI-1 have a lower body weight, lower adipose tissue mass, 
intraperitoneal fat and an improved metabolic profile.16 Taken together, it is still not appar-
ent how PAI-1 is involved in obesity and insulin resistance.
PAI-1 is known to be synthesized by various tissues including liver and adipose tissue. 
Increased plasma PAI-1 levels can result from increased expression from the adipose tis-
sue. Increased mRNA expression of PAI-1 is positively correlated with obesity in human and 
rodents.7,8,11 Alternatively, increased plasma PAI-1 can result from decreased plasma PAI-1 
clearance. We previously showed that increased plasma PAI-1 levels result from decreased 
clearance in mice overexpressing receptor-associated protein, the low-density lipoprotein 
receptor gene family.
In the current study, we investigated the plasma PAI-1 levels during the development of 
insulin resistance. Additionally, we studied the contribution of the clearance of PAI-1 in insu-
lin resistance. For this purpose, we used both diet-induced and genetically insulin resistant 
mouse models. Here, we show that the plasma PAI-1 levels increase in insulin resistance. 
Moreover, the increased plasma PAI-1 levels follow rather than precede insulin resistance. 
Furthermore, we also showed that the increased plasma PAI-1 levels are not due to delayed 
clearance in both diet-induced and genetically obese insulin resistant mice. Our data do not 
support the concept that PAI-1 has a direct causal role in insulin resistance. Plasma PAI-1 
levels merely increase in response to insulin resistance










Twelve weeks old male wild-type C57Bl/6 mice (Charles River, Maastricht, The Nether-
lands) were housed in a temperature and humidity-controlled room on a 12:12-h light-dark 
cycle. Mice were fed a high fat diet (45 energy%, HFD) or a control diet (10 energy%, control) 
with fat derived from palm oil (Hope Farms, Woerden, The Netherlands). Male db/db mice 
(Charles River, Maastricht, The Netherlands) and their respective C57Bl/6 control mice 
were fed regular chow diet. Mice had free access to water.
All animal experiments were approved by the Animal Ethics Committee from the Leiden 
University Medical Center, Leiden, The Netherlands.
Blood sampling and analysis
For glucose and insulin measurements, blood was collected in EDTA-coated vials by tail 
bleeding. For PAI-1 antigen measurements, blood samples were obtained collected in vials 
containing 1/10 volume of 3.2% (w/v) citrate. Plasma was prepared by centrifugation (8000xg 
for 10 minutes at 4°C), snap-frozen and stored at -80°C prior to analysis. Mouse plasma 
PAI-1 antigen (Innovative Research, CA) was determined by enzyme-linked immunosorbent 
assay (ELISA) according to manufacturer’s instructions. Plasma glucose was determined 
using commercially available kits (Instruchemie, Delftzijl, The Netherlands). Insulin was 
determined by a mouse insulin ELISA (Mercodia, Uppsula, Sweden). Exogenous PAI-1 decay 
experiments were performed as previously described.17 In short, mice received a bolus of 
1 µg/mouse purified latent murine PAI-1 (Innovative research, CA) via the tail vein.  Values 
are expressed as percentage of PAI-1 remaining in the circulation, with the amount of PAI-1 
present at 1 minute after injection considered as 100%. An one phase exponential fit was 
used to calculate the half-lifes (t1/2).
Hyperinsulinemic euglycemic clamp experiments
Hyperinsulinemic euglycemic clamps experiments were performed as described.18  Mice 
were fasted overnight with food withdrawn at 5 p.m. the day prior to the experiments. Mice 
were anesthetised with 6.25 mg/kg acepromazine (Alfasan, Woerden, The Netherlands), 6.25 
mg/kg midazolam (Roche, Mijdrecht, The Netherlands) and 0.31 mg/kg fentanyl (Janssen-
Cilag, Tilburg, The Netherlands). Basal glucose turnover was determined by a continuous 
infusion of 14C-glucose (GE Healthcare, Little Chalfont, U.K.) for 60 minutes. Subsequently, 
insulin was administered for 90 minutes to attain steady state circulating insulin levels of 
~4 ng/ml. A 12.5% D-glucose solution was used to maintain euglycemia as determined at 
10 min intervals via tail bleeding with a hand glucose monitor (Accu-chek, Sensor Comfort, 
Roche Diagnostics GmbH, Mannheim, Germany). Blood samples (60 μl) were taken during 
Lihui_10.indd   34 19-1-2009   11:50:00
 The clearance of plasma PAI-1 is not affected in insulin resistant mice  35
the basal period (after 50 and 60 min) and during the hyperinsulinemic period (after 70, 80, 
and 90 min) to determine plasma concentrations of glucose and insulin.
Statistical analysis
Data are analysed by means of the Mann-Whitney U test. P < 0.05 was regarded as statisti-
cally significant.
Results
Body weight, plasma glucose and insulin levels in mice on a high fat diet
Male C57B1/6 mice were fed a high fat diet (HF) to induce insulin resistance. The body weight 
was determined at baseline, and at 4 and 12 weeks after high fat diet (HFD) or control diet. 
A significant increase in body weight in the HFD group was already observed from 4 weeks 
of HFD on (Figure 1). To confirm insulin resistance, we performed hyperinsulinemic eugly-
cemic clamp analyses.18 The glucose infusion rate (GIR) was significantly lower in mice fed 
the HFD after 4 and 12 weeks as compared to mice fed the control diet, confirming rapid 
onset (i.e. 4 weeks) of insulin resistance (Figure 2).
Plasma PAI-1 levels and clearance in diet-induced insulin resistant mice
Plasma PAI-1 levels were measured in time to study when plasma PAI-1 levels will increase 
during the development of insulin resistance. Plasma PAI-1 levels were not affected until 
12 weeks of HFD feeding. In HFD-induced insulin resistant mice, plasma PAI-1 levels were 
similar between the control and HFD groups after 4 and 8 weeks of diet (Figure 3). However, 
after 12 weeks of HFD plasma PAI-1 levels were significantly increased as compared to 
the control diet (Figure 3). This increase was still present after 16 weeks of HFD.  We next 
examined whether altered clearance of PAI-1 contributed to the observed increased plasma 
PAI-1 levels under prolonged HFD feeding conditions. Plasma PAI-1 clearance of intrave-
nously administered purified murine PAI-1 were studied in diet-induced insulin resistant 
mice after 4 and 16 weeks of HFD or control diet. Not surprisingly, the plasma PAI-1 decay 
after 4 weeks of diet was not different between the control and HF diet groups, since plasma 
PAI-1 levels were similar between the groups (Figure 4). The half-lives at 4 weeks of diet 
were 12.9 ± 4.7 and 9.8 ± 3.0 minutes for control and HF group, respectively. However, after 
16 weeks of HFD, the decay was also not affected by HFD as compared to control diet (Figure 
4). The half-lives were 8.5 ± 1.6 and 7.9 ± 1.4 for HFD and control diet, respectively. Taken 
together, the increase of plasma PAI-1 levels followed the development of insulin resistance 
and this increase was not the consequence of decreased plasma clearance.























Figure 1 Body weight
Body weight of twelve weeks old male C57Bl/6 mice (Charles River, Maastricht, The Netherlands) at base 
line, 4 and 12 weeks of HFD (45 energy%) or control diet (10 energy%). The HFD and the control diet group 

















Figure 2 Glucose infusion rate
Glucose infusion rate as measured by hyperinsulinemic euglycemic clamp after 4 and 12 weeks of diet. GIR: 
glucose infusion rate. . **P < 0.01, significantly different from the control group.
Plasma PAI-1 levels and clearance in genetically insulin resistant mice
To investigate whether elevated plasma PAI-1 levels were related to genetically insulin 
resistance, we measured plasma PAI-1 levels and plasma PAI-1 clearance in db/db mice. 
The body weight of db/db mice was significantly higher as compared to wild-type C57B6/J 
mice (48.5 ± 3.0 vs. 22.9 ± 1.3, P < 0.0001). Plasma PAI-1 levels were about 5-fold higher in 
the genetically insulin resistant db/db mice as compared to wild-type C57B6/J mice consist-
ent with previous findings (Figure 5A).19
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Similar as in the diet-induced obese insulin resistance mice, plasma PAI-1 clearance was 
similar between the db/db and wild-type C57B6/J mice (Figure 5B). The plasma PAI-1 half-
lives were 10.7 ± 5.5 and 9.1 ± 2.4 minutes for db/db and wild-type C57B6/J mice, respec-





























Figure 3 Plasma PAI-1 levels in time























Figure 4 Plasma PAI-1 clearance in diet-induced insulin resistant mice
Plasma PAI-1 half-lives of diet-induced insulin resistant mice. A one-exponential fit was used to calculate 
the half-lives, considering the amount of PAI-1 present at 1 minute after injection as 100%.
















































Figure 5 Plasma PAI-1 levels and clearance in genetically insulin resistant db/db mice
(A) Plasma PAI-1 levels of genetically insulin resistant 12-weeks old db/db mice (grey bars) and control 
wild-type (WT) C57Bl/6 mice (white bars). (B) Plasma PAI-1 half-lives of db/db and WT mice. ***P < 0.001, 
significantly different from control WT C57Bl/6J mice.
Discussion
The aim of the current study was to investigate the plasma PAI-1 levels in the development 
of insulin resistant mice. In addition, the clearance of plasma PAI-1 levels was studied in 
diet-induced and genetically insulin resistant mice. We showed that the increase of plasma 
PAI-1 levels follows the insulin resistance rather than preceding insulin resistance. Fur-
thermore, the increased plasma PAI-1 levels do not find its origin in delayed clearance.
Several epidemiological studies have shown that plasma PAI-1 can predict the develop-
ment of diabetes independently from other known risk factors.3,4 The progression of PAI-1 
plasma levels in addition to initial high plasma levels is thought to be associated with inci-
dent diabetes.6 PAI-1-deficient mice do not develop insulin resistance and have improved 
metabolic profiles, suggesting a causal relation between PAI-1 and insulin resistance.13,14 
However, our data do not support these previous findings. We showed that the increase 
of plasma PAI-1 levels follows insulin resistance rather than precede insulin resistance. 
Insulin resistance was already present as early as 4 weeks of HFD, whereas plasma PAI-1 
levels increased only after 12 weeks of HFD. Lower insulin levels and higher glucose levels 
were observed in mice overexpressing PAI-1.16 The PAI-1 deficient mouse model by Mor-
ange et al. 15 has improved metabolic profiles. These data together with our results suggest 
that PAI-1 does not have a causal role in the development of insulin resistance.  Increased 
plasma PAI-1 levels may be of clinical relevance, but a pathophysiologically epiphenomenon 
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of the inflammatory setting of insulin resistance. Improvement of the insulin resistance and 
thereby the inflammatory setting may also result in decreased plasma PAI-1 levels.24
The increased plasma PAI-1 in insulin resistance is thought to be the result of increased 
expression by the adipose tissue.20,21 However, decreased plasma PAI-1 clearance may 
also result in increased plasma PAI-1 levels. We now show that the clearance of PAI-1 in 
both genetically and diet-induced insulin resistant mice models, does not contribute to the 
plasma PAI-1 levels. Therefore, the increased plasma PAI-1 levels are most likely the result 
of increased expression. PAI-1 is expressed in several tissues, including the adipose tis-
sue, the liver and the endothelium. The expression of PAI-1 in the liver was similar between 
insulin resistant and control mice (data not shown). Insulin resistance is associated with 
endothelial dysfunction.22,23 The main physiological function of PAI-1 is the inhibition of fibri-
nolysis of a thrombus present in the blood vessel after endothelial damage. Therefore, the 
vascular endothelium might also be an important source of increased PAI-1 expression in 
insulin resistance in addition to the adipose tissue.
In conclusion, our data demonstrate that increased plasma PAI-1 levels follow insulin resis-
tance rather than precede insulin resistance. This plasma PAI-1 elevation does not find its 
origin in delayed plasma clearance.
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Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) are associated with 
increased obesity, insulin resistance and cardiovascular diseases. While research has been 
directed towards the production of PAI-1, the clearance of PAI-1 remains poorly under-
stood. In vitro studies have demonstrated that PAI-1 is bound, internalised and degraded by 
the low-density lipoprotein receptor (LDLR)-related protein (LRP). In the present study, we 
have investigated the role of hepatic LRP in the clearance of plasma PAI-1 in vivo, employing 
mice conditionally lacking hepatic LRP (LRP-). Plasma PAI-1 levels were similar between 
LRP- and control LRP+ littermates. LRP status also did not affect the clearance of both 
exogenously infused purified murine PAI-1 and endogenously endotoxin-stimulated PAI-1. 
Remarkably, adenovirus-mediated gene transduction of the LDLR gene family antagonist 
receptor-associated protein (RAP) resulted in a significant increase of plasma PAI-1 in both 
LRP+ and LRP- mice. In addition, the plasma PAI-1 decay was prolonged 2-fold in mice over-
expressing RAP in the circulation. The plasma levels of PAI-1 in LDLR-/-, VLDR-/-, double 
deficient LRP-LDLR-/- and LRP-VLDLR-/- were not different from plasma PAI-1 levels in 
LRP+ mice. Therefore, we conclude that in contrast to the in vitro data, hepatic LRP does not 
contribute to the clearance of plasma PAI-1 to a significant extent.  In addition, we propose 
that RAP-sensitive mechanisms other than hepatic LRP, LDLR and VLDLR are involved in 
the clearance of PAI-1 in vivo.
Keywords: PAI-1, LRP, clearance, mice
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Introduction
Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of tissue-type 
and urokinase-type plasminogen activator (tPA, uPA). Increased plasma PAI-1 levels are 
strongly associated with obesity, diabetes and cardiovascular diseases.1,2 Furthermore, 
increased plasma PAI-1 levels are associated with decreased fibrinolysis.3 This increase 
is associated with enhanced PAI-1 expression in vascular endothelium, adipose tissue and 
liver.1 Alternatively, decreased plasma PAI-1 clearance might contribute to the increased 
plasma PAI-1 levels. However, it remains unknown how PAI-1 is cleared from the circula-
tion and to what extent decreased plasma PAI-1 removal contributes to increased plasma 
PAI-1 levels.
PAI-1 interacts with the low-density lipoprotein receptor (LDLR)-related protein (LRP) in 
vitro.4 LRP is a multi-ligand endocytic receptor of the LDLR gene family, which also includes 
LDLR and very low-density lipoprotein receptor (VLDR). All ligand binding to LDLR gene 
family members is antagonised by the receptor-associated protein (RAP). LRP is a multi-
ligand multifunctional receptor. It recognizes >30 structurally and functionally different 
ligands in vitro, including PAI-1.4,5 PAI-1 contains binding sites for the low-density lipopro-
tein receptor (LDLR)-related protein (LRP).6 In vitro studies have demonstrated that PAI-1 is 
bound, internalised and degraded by LRP.7 Multiple in vitro studies have shown that PAI-1 in 
complex with its target proteins is a better ligand for LRP than PAI-1 alone. However, PAI-1 
binds to LRP with similar affinity as factor VII (FVII), which is demonstrated to be regulated 
by LRP in vivo.6,8
In the present study, we studied the role of hepatic LRP in the regulation of plasma PAI-1 
levels in vivo.  To this end, we used the unique mouse model that allows Cre/loxP-medi-
ated deletion of hepatic LRP.9 In addition, we have addressed whether other RAP-sensitive 
mechanisms are involved in the clearance of plasma PAI-1 levels using adenovirus-medi-
ated gene transfer of RAP. We propose that RAP-sensitive pathways other than hepatic LRP, 
LDLR and VLDLR are involved in the clearance of plasma PAI-1 in mice.
Material and Methods
Plasma PAI-1 clearance in transgenic mice
We employed LRP, LDLR and VLDR deficient mice and combination thereof.9-11 Age-matched 
8-12-weeks old mice homozygous for the “floxed” LRP allele, either with or without the 
MX1Cre transgene (MX1Cre+LRPflox/flox or LRPflox/flox, respectively) littermates were used. 
LRP deficiency was induced as described.8,9 In clearance experiments, male mice received a 
bolus of 1 µg/mouse purified latent murine PAI-1 (Innovative Research, CA) via the tail vein. 
Values are expressed as percentage of PAI-1 remaining in the circulation, with the amount 








of PAI-1 present at 1 minute after injection considered as 100%. Data were corrected for 
endogenous PAI-1 levels. A one phase exponential fit was used to calculate the half-lives. 
For endogenous PAI-1 turnover, female mice received 5 µg of endotoxin (LPS Re 595, Sigma, 
MO) intraperitoneally as described.12 All animal experiments were approved by the institu-
tional committees on animal welfare of TNO-Quality of Life.
Plasma analysis
Blood samples were obtained by tail bleeding and collected in tubes containing 1/10 volume 
of 3.2% (w/v) citrate. Plasma was prepared by centrifugation (8000xg for 10 minutes at 4°C), 
snap-frozen and stored at -80°C prior to analysis. Mouse plasma PAI-1 antigen (Innova-
tive Research, CA) and serum amyloid A (SAA; Biosource Europe, Belgium) were measured 
by enzyme-linked immunosorbent assay according to manufacturers instructions. Mouse 
plasma FVIII activity was measured using an one-stage coagulation assay as described.13 
Pooled plasma of C57BL/6J mice was used as reference.
Recombinant adenovirus transduction
Recombinant adenovirus (1x109 plaque-forming units) containing RAP (Ad-RAP) or 
β-galactosidase cDNA (Ad-β-Gal) were used for in vivo transduction as described.14 Ad-
RAP gene transduction results in hepatic overexpression of secretable RAP in plasma. 
Blood samples were collected 8 days after adenovirus injection.  The PAI-1 decay experi-
ments were performed at 8 days after virus injection. Mice intravenously received a bolus 
of purified murine PAI-1 (1 µg per mouse) and plasma elimination of PAI-1 was followed in 
time. The functionality of Ad-RAP was evaluated by measuring plasma cholesterol levels in 
LDLR-/- mice as described.14
Statistical analysis
Data are represented as geometric means and 68% confidence intervals (CI), which rep-
resent one standard deviation from the geometric mean if a log-normal distribution is 
assumed. Data are analyzed by means of the Mann-Whitney U test. P < 0.05 was regarded 
as statistically significant.
Results and Discussion
Plasma PAI-1 levels and clearance in LRP deficient mice
In vitro studies have shown that LRP plays a major role in the catabolism PAI-1. To explore 
the physiological relevance of hepatic LRP in the regulation of plasma PAI-1 clearance, 
we measured plasma PAI-1 in induced MX1Cre+LRPflox/flox (LRP-, n = 31) mice and control 
LRPflox/flox (LRP+, n = 33) littermates (Figure 1A). LRP- mice displayed similar plasma levels 
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as controls. Plasma PAI-1 levels were 1.3 (1.2-1.5) ng/mL and 1.6 (1.4-1.8) ng/mL for LRP- 
and control LRP+ littermates, respectively (p = 0.19).  Significant increase in plasma FVIII 
 activity was observed in these LRP- [5.4 (5.0-5.9) U/mL] and LRP+ [2.7 (2.1-3.4) U/mL] mice 
(P < 0.05), which is consistent with our previous findings, indicating adequate induction of 











































Figure 1 Plasma PAI-1 antigen and FVII activity in hepatic LRP deficient mice LRP.
Plasma PAI-1 antigen levels (A) and FVII activity (B) in LRP deficient (LRP-, n = 31) and control littermates 
(LRP+, n = 33).  **p < 0.01, significantly different from control LRP+ littermates.






















Figure 2 Plasma PAI-1 clearance in hepatic LRP deficient mice
LRP- and control LRP+ littermates (n = 6) intravenously received a bolus of purified mice PAI-1 (1 µg/
mouse) and the plasma elimination of PAI-1 was followed in time. A one-exponential fit was used to 
calculate the half-lives, considering the amount of PAI-1 present at 1 minute after injection as 100%.




































Figure 3 Plasma PAI-1 antigen and clearance of plasma PAI-1 upon LPS challenge
LRP- (n = 8) and control LRP+ (n = 7) littermates intraperitoneally received 5 µg/mouse endotoxin LPS.  
Subsequently, plasma PAI-1 was measured during 24-hours. 
























Figure 4 Plasma PAI-1 clearance in mice overexpressing RAP
Mice intravenously received 1 x 109 plaque forming units of recombinant Ad-β-Gal or Ad-RAP (n = 6). Eight 
days after adenovirus administration, mice intravenously received a bolus of purified murine PAI-1 (1 µg/
mouse) and the plasma elimination of PAI-1 was followed in time as in figure 2. **p < 0.01, significantly 
different from Ad-β-Gal treated mice.
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of PAI-1, we studied the plasma elimination of intravenously administered purified murine 
PAI-1.  PAI-1 half-lives were identical between LRP- and LRP+ littermates (Figure 2). The 
half-lives were calculated to be 4.3 (3.7-4.3) minutes and 4.3 (3.7-4.3) minutes for LRP- and 
LRP+, respectively.
It has been established that lipopolysaccharide (LPS) can induce increased plasma PAI-1 
levels in mice.12 Therefore, we challenged LRP- and LRP+ mice with endotoxin to induce a 
transient rise in endogenous plasma PAI-1 levels. Indeed, upon LPS challenge a transient 
rise in endogenous plasma PAI-1 levels was observed (Figure 3). More importantly, the sub-
sequent plasma PAI-1 elimination in LRP- and LRP+ littermates was similar (Figure 3). The 
areas under the curve were 2.8 (2.3-3.5) µg/mL.h and 2.1 (1.6-2.8) µg/mL.h for LRP- and 
LRP+ mice, respectively (p = 0.61). These data indicated that hepatic LRP is not involved in 
the regulation of plasma PAI-1 levels to a significant extent in vivo.
Adenovirus-mediated overexpression of RAP in hepatic LRP deficient mice
In vitro studies have previously demonstrated that the LDLR gene family antagonist recep-
tor-associated protein (RAP) inhibits the endocytosis and degradation of PAI-1.15 Hence, we 
investigated whether RAP-dependent mechanisms other that hepatic LRP are involved in 
the regulation of plasma PAI-1 levels.  Administration of adenovirus containing RAP cDNA 
(Ad-RAP) evoked a significant increase in plasma PAI-1 levels in both LRP+ and LRP- mice, 
as compared to mice that received control adenovirus containing β-galactosidase cDNA 
(Ad-β-Gal, Table 1). However, no difference in plasma PAI-1 levels was observed between 
LRP+ and LRP- mice following Ad-RAP administration (P = 0.49). As plasma PAI-1 levels 
also increased after Ad-β-Gal administration, we considered the possibility that the plasma 
PAI-1 increase is due to an acute phase reaction upon adenovirus administration. There-
fore, we measured the acute phase protein SAA. Indeed, adenoviral administration resulted 
in a significantly increased SAA. However, the increased SAA was more pronounced in mice 
that received Ad-β-Gal as compared to Ad-RAP. Plasma SAA levels were 2.1 (0.8-5.1) µg/mL 
and 99.7 (82.3-120.8) µg/mL for Ad-RAP and Ad-β-Gal, respectively (P < 0.05).  This strongly 
suggests that the increased plasma PAI-1 in mice overexpressing RAP is independent of the 
systemic inflammatory response to adenovirus. Of note, although injection were standard-
ized according to the plaque forming units, the absence of a SAA elevation following Ad-
RAP likely reflects difference in Ad-β-Gal and Ad-RAP batches with regard to the content 
of non-infectious viral particles. However, we cannot fully exclude the possibility that RAP 
itself modulates SAA levels.








Table 1 Plasma PAI-1 in control, LRP-, LDLR-/-, VLDLR-/-, LRP-LDLR-/- and LRP-VLDLR-/- mice with and 
without adenovirus-mediated overexpression of RAP.
genotype adenovirus PAI-1 (ng/mL) n
LRP+ - 1.6 (1.4-1.8) 33
LRP- - 1.3 (1.2-1.5) 31
LRP+ ad-β-Gal 32.5 (24.9-42.3) 4
LRP+ ad-RAP 159.3 (98.9-256.6)* 4
LRP- ad-β-Gal 19.6 (11.7-33.0) 4
LRP- ad-RAP 261.9 (192.2-357.0)# 4
LDLR-/- - 1.5 (1.4-1.6) 14
VLDLR-/- - 2.1 (1.8-2.3) 5
LRP-LDLR-/- - 1.6 (1.4-1.8) 16
LRP-VLDLR-/- - 1.7 (1.5-2.0) 7
For the adenovirus-mediated overexpression of RAP, mice received 1x109 plaque forming units recombinant 
adenovirus containing RAP (Ad-RAP) or control β-galactosidase (Ad-β-Gal) cDNA. Blood samples were collected 5 days 
after adenovirus administration. Blood samples were then analysed for PAI-1. Data represent geometric mean with 
68% CI. *p < 0.05, significantly different from ad-β-Gal injected LRP+ mice. #p < 0.05, significantly different from ad-β-
Gal injected LRP- mice.
To study whether the increased plasma PAI-1 levels in Ad-RAP treated mice can be attrib-
uted to impaired clearance, we followed the clearance of exogenously injected PAI-1 in 
these mice. The clearance of PAI-1 was 2-fold slower in mice overexpressing RAP (Figure 
4). The half-lives were calculated to be 15.4 (13.3-18.4) minutes in Ad-RAP treated mice 
and 8.3 (7.6-9.1) minutes in mice that received Ad-β-Gal (P < 0.01). These data indicate that 
RAP-dependent mechanisms other than hepatic LRP are involved in the regulation of PAI-1 
in vivo.
RAP-sensitive receptors include LDLR and VLDLR. Therefore, we measured plasma PAI-1 
levels in LDLR-/-, VLDLR-/-, and double deficient LRP–LDLR-/- and LRP– VLDLR-/- mice. 
Plasma PAI-1 levels in these mice were not different from plasma PAI-1 in LRP+ mice (Table 
1), suggesting that neither LDLR nor VLDLR is critically involved in the regulation of plasma 
PAI-1 levels. Additional studies are required to establish which RAP-sensitive mechanisms 
are involved in the regulation of plasma PAI-1 levels. The question remains whether the 
LRP/PAI-1 interaction is of any physiological importance. It could be possible that the inter-
action between LRP and PAI-1 is of importance only when PAI-1 is in complex with its target 
proteases. The high affinity LRP binding site in PAI-1 is demonstrated to be exposed when 
PAI-1 is in complex with t-PA.4 However, the similar plasma PAI-1 levels between LRP- and 
LRP+ (Figure 1) are a strong argument against a significant accumulation of plasma PAI-1 
complexes in the present study. Alternatively, the PAI-1/LRP interaction might only be of 
importance in cellular signaling locally. It has been shown that PAI-1 is a potent chemoat-
tractant molecule, an activity that depends on the interaction with LRP for cell signalling.16 
Identification of the molecular mechanisms that underlie the regulation of PAI-1 levels in 
the circulation may further advance our understanding of increased plasma PAI-1 levels in 
patients with obesity, diabetes and cardiovascular diseases.
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Lipoprotein lipase (LPL) activity plays an important role in preceding the remnant clear-
ance via the three major apoE-recognizing receptors, the LDL receptor (LDLr), LDLr related 
protein (LRP), and VLDL receptor (VLDLr). We recently showed that lrp-ldlr-/-vldlr-/- mice 
have elevated fasted plasma total cholesterol (TC) and triglyceride (TG), mainly present as 
VLDL. However, since VLDL is continuously produced by the liver, their core remnants must 
thus still be cleared to attain steady state lipid levels in plasma. The aim of this study was 
to determine whether LPL activity is important for the clearance of VLDL core remnants 
irrespective of these receptors, and to determine the mechanisms involved in the hepatic 
uptake of these remnants. Administration of an adenovirus expressing LPL (AdLPL) into 
lrp-ldlr-/-vldlr-/- mice reduced both VLDL-TG and VLDL-TC levels. Conversely, inhibition of LPL 
by AdAPOC1 increases plasma VLDL-TG and VLDL-TC levels. Metabolic studies with radio-
labeled VLDL-like emulsion particles showed that the clearance and hepatic association 
of their core remnants positively correlated with LPL activity. This hepatic association was 
independent of the bridging function of LPL and HL, since heparin did not reduce the liver 
association. In vitro studies demonstrated that VLDL-like emulsion particles avidly bound to 
the cell surface of primary hepatocytes from lrp-ldlr-/-vldlr-/- mice, followed by slow internal-
ization, and involved heparin-releasable cell surface proteins as well as scavenger receptor 
BI (SR-BI). Collectively, we conclude that hepatic VLDL remnant uptake in absence of the 
three classical apoE-recognizing receptors is regulated by LPL activity and involves hepa-
ran sulfate proteoglycans and SR-BI.
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Introduction
Lipoprotein lipase (LPL) is the key enzyme responsible for hydrolysis of triglycerides (TG) in 
TG-rich lipoproteins such as chylomicrons and VLDL (1, 2). During lipolysis, the lipoproteins 
are reduced in size and enriched with apoE. Subsequently, their core remnants are taken 
up mainly by the liver via apoE-recognizing receptors, i.e. the LDL receptor (LDLr) and the 
LDLr related protein (LRP) (2). Therefore, mice deficient for the LDLr and hepatic LRP show 
marked accumulation of TG-rich lipoprotein remnants (3). Although core remnants may be 
directly internalized via the LDLr, the binding and internalization via the LRP is thought to 
involve previous binding of core remnants to heparan sulfate proteoglycans (HSPG) in the 
space of Disse via heparin-binding proteins such as apoE (4, 5).
The third major apoE-recognizing receptor, the VLDL receptor (VLDLr), is expressed abun-
dantly in tissues active in fatty acid metabolism (i.e. heart, skeletal muscle, and white adi-
pose tissue), and functions as a peripheral lipoprotein remnant receptor. Like the LDLr and 
LRP, the VLDLr binds TG-rich lipoproteins via apoE and this binding is modulated by LPL 
(6, 7). VLDLr-deficient mice have normal plasma lipoprotein levels when fed a chow diet (8). 
However, when TG metabolism is stressed by feeding a high fat diet or by cross-breeding 
on an ob/ob or ldlr-/- background, the VLDLr deficiency results in moderate accumulation of 
plasma TG-rich lipoproteins (9, 10). Recently, we demonstrated that the VLDLr plays a major 
role in postprandial lipoprotein metabolism by facilitating LPL-mediated TG hydrolysis (11).
Additional deletion of the VLDLr from LDLr- and hepatic LRP-double deficient mice aggra-
vates their phenotype upon stressing TG metabolism, either by high-fat feeding or by giving 
an intragastric olive oil bolus (12). On a chow diet, the steady state fasted plasma TG and total 
cholesterol (TC) levels are 8-9-fold increased in lrp-ldlr-/-vldlr-/- mice as compared to wild-
type mice (12). However, because lrp-ldlr-/-vldlr-/- mice have continuous lipid input into their 
circulation via the production of VLDL similar to wild-type mice, the remnants in these mice 
must be cleared from plasma to maintain the steady state lipid levels. This indicates that, 
although less efficient than via the classical remnant receptors, additional pathway(s) are 
present for the clearance of lipoprotein remnants in vivo.
Two of these non-classical pathways may involve HSPG and the scavenger receptor BI (SR-
BI). HSPG have been reported to directly internalize apoE-enriched TG-rich particles, both 
in vitro (13) and in vivo (14). In fact, under normal physiological conditions hepatic HSPG are 
critically important for the clearance of remnant lipoproteins, since targeted inactivation 
of the biosynthetic gene Ndst1 in hepatocytes, resulting in 50% reduction in sulfation of 
liver heparan sulfate, resulted in accumulation of TG-rich lipoproteins in wild-type as well 
as ldlr-/- mice (15). In addition, recent studies using srb1-/- mice have shown that SR-BI can 
function as an internalizing receptor for chylomicrons (16, 17) and VLDL (18).
Sehayek et al. (19) showed that the lipolytic activity of LPL (i.e. hydrolysis of TG within the 
lipoprotein core) is a requisite for apoE-dependent uptake of lipoprotein remnants via the 








LDLr and possibly the LRP in vitro. However, it remains unclear whether modulation of LPL 
activity also affects the catabolism of TG-rich particles in the absence of the three major 
apoE-recognizing receptors in vivo, e.g. via HSPG and/or SR-BI. Therefore, the aim of this 
study was to determine the role of LPL activity in hepatic VLDL metabolism in mice that lack 
the LDLr, hepatic LRP, and the VLDLr, as well as the mechanisms involved in the hepatic 
uptake. Hereto, we either increased LPL activity by adenovirus-mediated overexpression 
(20) or decreased LPL activity by adenovirus-mediated expression of the LPL-inhibitor apoCI 
(21). In these studies, we demonstrate that the receptor-independent hepatic uptake of VLDL 
core remnants in vivo is regulated by LPL activity and involves HSPG and SR-BI.
Materials and methods
Animals
Male MX1Cre+lrploxP/loxPldlr-/-vldlr-/- mice (12), 4-6 months of age were used in experiments. 
Mice were obtained from our breeding colony at the Institutional Animal Facility and housed 
under standard conditions in conventional cages and were fed regular chow ad libitum. LRP 
deficiency was induced by intraperitoneal injection of polyinosinic:polycytidylic ribonucleic 
acid (pI:pC, Sigma, St Louis, MO, U.S.A.), which results in the complete absence of LRP pro-
tein in liver membrane extracts (12). These mice will be further referred to as lrp-ldlr-/-vldlr-/-. 
Experiments were performed after 4 h of fasting at 12:00 pm with food withdrawn at 8:00 
am, unless indicated otherwise. The Institutional Ethical Committee on Animal Care and 
Experimentation has approved all experiments.
Adenoviruses and administration to mice
The generation of an adenovirus expressing human apoCI (AdAPOC1) has been described 
in full detail (21). An adenovirus expressing human LPL (AdLPL) 1 was a kind gift of Dr. Silvia 
Santamarina-Fojo. An adenovirus expressing ß-galactosidase (AdLacZ) was used as con-
trol. Viruses were grown and purified by standard procedures and typical titers of 1x1010 
– 1x1011 pfu/mL were obtained. Viruses were stored in aliquots at –80°C until use. Basal 
serum lipid levels were measured 4 weeks after pI:pC injection, at least 3 days before aden-
ovirus injection into mice. At day 0, mice were injected into the tail vein with either AdAPOC1, 
AdLPL or AdLacZ (1x109 pfu/mouse), diluted with PBS to a total volume of 200 µL. To prevent 
sequestration of low doses of virus by Kupffer cells, mice were pre-injected with 0.5x109 pfu 
AdLacZ at 3 h before injection of the adenoviruses of interest (22).
Plasma lipid and lipoprotein analysis
In all experiments blood was collected from the tail vein into chilled paraoxon (Sigma, St. 
Louis, MO, U.S.A.)-coated capillary tubes to prevent ongoing in vitro lipolysis (23). The tubes 
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were placed on ice, centrifuged at 4°C, and the obtained plasma was assayed for TC and TG, 
using the commercially available enzymatic kits 236691 and 11488872 (Roche Molecular 
Biochemicals, Indianapolis, IN, U.S.A), respectively. For determination of the distribution of 
lipids over plasma lipoproteins by fast-performance liquid chromatography (FPLC), 50 µL of 
pooled plasma per group was injected onto a Superose 6 column (Äkta System; Amersham 
Pharmacia Biotech, Piscataway, NJ, U.S.A.), and eluted at a flow rate of 50 µL/min with 
PBS, 1 mM EDTA, pH 7.4. Fractions of 50 µL were collected and assayed for TC and TG as 
described above.
Post-heparin plasma LPL levels
Blood was collected 10 min after tail vein injection of heparin diluted in PBS (0.1 U/g body 
weight; Leo Pharmaceutical Products B.V., Weesp, The Netherlands). Plasma was iso-
lated, snap-frozen, and stored at –80°C until analysis for total LPL activity as previously 
described (24).
Preparation of VLDL-like emulsion particles
TG-rich VLDL-like emulsion particles (80 nm) were prepared as described (25). Emulsions 
were obtained by adding the following labels to 100 mg of emulsion lipids prior to sonica-
tion: 1) 200 µCi of glycerol tri[3H]oleate (triolein, TO) and 20 µCi of [14C]cholesteryl oleate 
(CO), 2) 500 µg of 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanide perchlorate (DiI) 
(Molecular Probes, Leiden, The Netherlands), or 3) 80 µCi of [3H]cholesteryl oleoyl ether 
(COEth).
In vivo kinetics of VLDL-like emulsion particles
The in vivo kinetics of [3H]TO and [14C]CO-double labeled emulsion particles were assessed 
at five days after virus administration. Hereto, mice were anaesthetized with acepromazine: 
midazolam: fentanyl (1:2:5, v/v/v), the abdominal cavities were opened, and the radiolabeled 
emulsion particles (1.0 mg TG in 200 µL of PBS) were injected into the vena cava inferior at 
8:00 am. In addition, the effect of heparin on the kinetics of emulsion particles was evalu-
ated. Hereto, mice were anaesthetized and the radiolabeled emulsion particles (1.0 mg TG 
in 200 µL of PBS) were administered into the tail vein 10 min after i.v. injection of heparin 
(500 U/kg) or PBS at 8:00 am. At indicated time-points after injection, blood was taken from 
the vena cava inferior or tail vein, to determine the serum decay of [3H]TO and [14C]CO by 
scintillation counting (Packard Instruments, Dowers Grove, IL, U.S.A.). At 30 minutes after 
injection, mice were sacrificed and tissues were collected, including liver, heart, skeletal 
muscle, and white adipose tissue (WAT). Since the various WAT compartments can have dif-
ferent LPL activity levels (26), we analyzed both perirenal, intestinal, and gonadal WAT. Tis-
sues were weighed and dissolved o/n in Solvable (Packard Bioscience, Meriden, CT, U.S.A.), 
where after 3H- and 14C-activities were determined in Ultima Gold (Packard Bioscience). 








Radioactivity values were corrected for the serum radioactivity (liver, 84.7 µL/g; heart, 68.1 
µL/g; white adipose tissue, 16.1 µL/g; skeletal muscle, 13.7; µL/g) present at the time of 
sampling (25). The total plasma volumes of the mice were calculated from the equation V 
(mL) = 0.04706 x body weight (g), as determined from 125I-BSA clearance studies as previ-
ously described (27).
Visualisation of uptake of fluorescently labeled VLDL-like emulsion particles by isolated mouse 
hepatocytes
Mouse hepatocytes were isolated from anesthetized wild-type or lrp-ldlr-/-vldlr-/- mice and 
subjected to Percoll® gradient centrifugation to discard nonviable cells (28). The cells (viabil-
ity >99% as judged from 0.2% trypan blue exclusion) were attached to collagen S-coated 
(3.87 µg/cm2) 2.5 cm glass cover slips in 9.6 cm2 6-well dishes (0.8 × 106 cells/well) by cultur-
ing in DMEM+10% fetal calf serum (3-4 h at 37 °C). The cover slips were washed to remove 
unbound cells and incubated (2 h at 4°C) with DiI-labeled VLDL-like emulsion particles (100 
µg TG/mL). The cover slips were washed twice with DMEM+2% BSA to remove unbound par-
ticles, and transferred to a Zeiss IM-35 inverted microscope (Oberkochen, Germany) with a 
Zeiss plan apochromatic 63×/1.4 NA oil objective and fitted with a temperature-controlled 
incubation chamber, which was equipped with a Bio-Rad 600 MRC confocal laser scanning 
microscopy system. The cells were further incubated (30 min at 37 °C) in DMEM+2% BSA, 
after which the (intra)cellular localization of DiI was visualized (λex 543 nm).
Association of radiolabeled HDL and VLDL-like emulsion particles with isolated mouse hepatocytes
Mouse hepatocytes were isolated from anesthetized wild-type or lrp-ldlr-/-vldlr-/- mice (28). 
Cells (1-2 mg protein/mL) were incubated (3 h at 37°C) in DMEM+2% BSA with [3H]COEth-
labeled HDL (20 µg protein/mL) or emulsion particles (100 µg TG/mL) in the absence and 
presence of oxidized LDL (oxLDL; 100 µg protein/mL) or heparin (1000 U/mL) under gentle 
shaking in a circulating lab shaker (Adolf Kühner AG, Basel, Switzerland) at 150 rpm. After 
incubation, cells were pelleted by centrifugation (1 min at 50 g), and unbound radiolabeled 
ligands were removed by washing twice with ice-cold 50 mM Tris.HCl, 150 mM NaCl, 5 mM 
CaCl2 (Tris-buffered saline), pH 7.4, containing 0.2% BSA, and once with Tris-buffered 
saline without BSA. The cell pellet was lysed in 0.1 M NaOH and the cell-associated radio-
activity and protein content was measured. [3H]COEth association was calculated as dpm 
per mg cell protein.
Statistical analysis
All data are presented as means ± S.D. Data were analyzed using the Mann-Whitney U-test 
unless indicated otherwise. P-values less than 0.05 were regarded as statistically significant.
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Results
LPL activity modulates VLDL-cholesterol levels in lrp-ldlr-/-vldlr-/- mice
To study the impact of LPL activity on the clearance of VLDL-associated TG and choles-
terol in the absence of the apoE-recognizing receptors, we used mice deficient for the LDLr, 
hepatic LRP, and VLDLr, as previously described (12). Upon deletion of hepatic LRP from 
MX1Cre+lrplox/loxldlr-/-vldlr-/- mice, their plasma lipid levels were determined and the mice 
were assigned to three groups, matched for TC and TG plasma levels (Table 1). The mice 
received AdLPL to increase LPL levels 2, AdAPOC1 to inhibit LPL activity 3, or AdLacZ as a 
control group. The effect of these interventions on plasma lipid levels was assessed at 5 
days after injection.
Table 1 Effect of adenovirus administration on plasma lipid levels and post-heparin LPL plasma activity in 
lrp-ldlr-/-vldlr-/- mice
LPL activity TG TC
(µmol FFA generated/h/mL) (mM) (mM)
Before adenovirus
AdLPL n.d. 3.9 ± 0.7 19.5 ± 3.0
AdLacZ n.d. 4.0 ± 0.8 19.4 ± 3.3
AdAPOC1 n.d. 3.8 ± 0.6 19.5 ± 8.1
After adenovirus
AdLPL 33.7 ± 5.4a 1.1 ± 0.1b 15.7 ± 3.9a
AdLacZ 11.4 ± 1.6 7.5 ± 0.9 19.0 ± 1.9
AdAPOC1 11.5 ± 7.6 37.6 ± 10.1b 30.1 ± 6.7b
Plasma was obtained from fasted lrp-ldlr-/-vldlr-/- mice before and after administration of AdLacZ, AdLPL, or AdAPOC1, 
and assayed for triglycerides (TG) and total cholesterol (TC). After the second blood withdrawal, heparin was injected 
and post-heparin plasma was obtained, and assayed for lipoprotein lipase (LPL) activity. Values are expressed as 
means ± S.D. n.d., not determined. Statistical differences were assessed as compared to AdLacZ. aP<0.05. bP<0.01.
AdLPL administration resulted in a 3.0-fold increase in post-heparin LPL plasma activity 
(33.7±5.4 vs 11.4±1.6 µmol FFA generated/h/mL; P<0.05), with a concomitant 6.8-fold reduc-
tion in plasma TG levels (1.1±0.1 vs 7.5±0.9 mM; P<0.01) and 1.2-fold reduction in plasma 
TC levels (15.7±3.9 vs 19.0±1.9 mM; P<0.05) as compared to mice administered with AdLacZ 
(Table 1). From FPLC fractionation of pooled plasma it was apparent that the decrease in 
plasma TG and TC was confined to the VLDL fractions (Fig. 1).
AdAPOC1 administration did not result in altered total post-heparin plasma LPL levels 
(11.5±7.6 vs 11.4±1.6 µmol FFA/h/mL) (Table 1). This is in accordance with previous findings 
that human APOC1 transgenic mice do not show a change in plasma total LPL levels as 
compared to wild-type mice (24), rather apoCI acts by modulating local LPL activity. Admin-
istration of AdAPOC1 resulted in 5.0-fold increased plasma TG levels (37.6±10.1 vs 7.5±0.9 
mM; P<0.01) in addition to 1.6-fold increased plasma TC levels (30.1±6.7 vs 19.0±1.9 mM; 








P<0.01) as compared to AdLacZ control mice (Table 1). These increased plasma TG and TC 
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Figure 1 Effect of modulation of LPL activity by LPL and apoCI on plasma triglyceride and total cholesterol 
distribution. 
Lrp-ldlr-/-vldlr-/- mice were injected with AdLacZ (open circles), AdLPL (open squares), or AdAPOC1 
(closed circles) (1x109 pfu). 4 Days after injection 4h fasted plasma samples were drawn, pooled, and 
subjected to FPLC fractionation. Fractions were analyzed for triglycerides (TG) (A) and total cholesterol 
(TC) (B). 
Taken together, these results suggest that LPL activity not only regulates the clearance 
of VLDL-TG, but also determines the clearance of VLDL-cholesterol in absence of the LRP, 
LDLr, and VLDLr in vivo.
LPL activity modulates the liver association of VLDL-like emulsion core remnants in lrp-ldlr-/-vldlr-/- 
mice
To provide direct in vivo evidence that LPL activity determines the clearance of VLDL-choles-
terol, [3H]TO and [14C]CO double-labeled TG-rich VLDL-like emulsion particles were injected 
into lrp-ldlr-/-vldlr-/- mice 5 days after AdLPL, AdAPOC1, or AdLacZ administration (Fig. 2).
The clearance of [3H]TO was substantially accelerated in AdLPL treated mice as compared 
to control mice, evidenced by a 2.5-fold decreased serum half-life of 3H-activity (t1/2=18±7 
vs 45±11 min) (Fig. 2A). On the other hand, mice that were treated with AdAPOC1 showed 
a 1.7-fold increased half-life (t1/2=77±13). Thus, the LPL activity was positively correlated 
with the serum clearance of 3H-activity (P<0.05). Increased LPL activity was accompanied 
by a significantly increased uptake of TO-derived 3H-activity in LPL-expressing organs as 
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heart (P<0.01), muscle (P<0.05), and WAT (P<0.05 for perirenal WAT), and also in the liver 
(P<0.01) (Fig. 2B).
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Figure 2 Effect of modulation of LPL activity by LPL and apoCI on the serum decay and organ distribution of 
VLDL-like emulsion particles. 
Lrp-ldlr-/-vldlr-/- mice were injected with AdLacZ, AdLPL, or AdAPOC1 (1x109 pfu). 5 Days after 
injection mice were anaesthetized and injected with [3H]TO and [14C]CO double-labeled emulsion 
particles (1 mg TG). Serum samples were collected at indicated times and measured for 3H-activity 
(A) and 14C-activity (C). At t=30 min the animals were sacrificed and tissues collected. Tissues were 
dissolved in Solvable (o/n at 60°C) and measured for 3H-activity (B) and 14C-activity (D), corrected 
for serum radioactivity. Asterisks indicate a statistically significant difference (*P<0.05; **P<0.01) as 
analyzed by one-way ANOVA (A, C) or Mann-Whitney U-test (B, D). pWAT, perirenal white adipose tissue 
(WAT); iWAT, intestinal WAT; gWAT, gonadal WAT.








Although serum [14C]CO decay was slower as compared to the [3H]TO decay, the [14C]CO serum 
half-life was also dependent on LPL activity. This was evidenced by a 1.4-fold decreased 
half-life of 14C-label in AdLPL treated mice (t1/2=71±24 min) and a 3.7-fold increased half-
life in AdAPOC1 treated animals (t1/2= 364±241 min) as compared to controls (t1/2= 99±8 
min) (P<0.05) (Fig. 2C). In addition, the association of 14C-activity with the liver was 7.0-
fold increased in AdLPL animals, as compared to control mice, and decreased to zero by 
AdAPOC1 (P<0.01) (Fig. 2D). Further analysis of the distribution of 14C-activity over choles-
terol and cholesteryl esters in the liver revealed that the 14C-activity was almost exclusively 
recovered in the cholesteryl esters (data not shown), which indicates that particles are 
indeed associated with the liver, however, they have not entered the lysosomal degradation 
pathway yet. Taken together, these results show that LPL activity positively correlates with 
liver association of particle core remnants.
Heparin accelerates the lipolysis of VLDL-like emulsion particles followed by rapid liver association of 
their core remnants in wild-type and lrp-ldlr-/-vldlr-/- mice
To gain insight into the potential pathways by which VLDL-like emulsion particles associate 
with the liver in absence of the LDLr, hepatic LRP, and VLDLr, we next determined the kinet-
ics of [3H]TO and [14C]CO double-labeled TG-rich VLDL-like emulsion particles in wild-type 
mice and lrp-ldlr-/-vldlr-/- mice following an i.v. injection of heparin (Fig. 3). Heparin results 
in the release of LPL from the vascular endothelium, resulting in a higher systemic plasma 
TG hydrolase activity, and prevents the association of both LPL and hepatic lipase (HL) with 
the liver.
In wild-type mice, heparin accelerated the serum clearance of both [3H]TO (t1/2 1.3±0.1 min 
vs 8.7±1.6 min) and [14C]CO (t1/2 2.9±0.1 min vs 12.0±2.4 min) (not shown). This was accom-
panied by a decreased uptake of [3H]TO-derived radiolabel by peripheral tissues and an 
increased uptake by the liver (Fig. 3A). [14C]CO-derived radiolabel mainly associated with 
the liver, both in the absence (35.0±5.1% of ID/g) and presence (41.3±7.0% ID/g) of heparin 
(Fig. 3B).
In lrp-ldlr-/-vldlr-/- mice, heparin also accelerated the serum clearance of both [3H]TO (t½ 
1.7±0.3 min vs 2.9±0.7 min) and [14C]CO (t½ 2.8±0.8 min vs 6.4±2.0 min) (not shown). The 
serum decay of the VLDL-like emulsion particles in lrp-ldlr-/-vldlr-/- mice was faster than 
observed in the previous experiment. This was probably due to the lower TG levels in this 
specific batch of mice at the time of the experiment (2.2±1.0 mM vs 4.0±0.8 mM) and the fact 
that infection of mice with a recombinant adenovirus per se did affect TG levels to some 
extent in the previous experiment (7.5±0.9 mM vs 4.0±0.8 mM). Similarly to wild-type mice, 
the increased lipolysis after heparin injection was accompanied by an increased associa-
tion of [3H]TO-derived radiolabel with the liver (Fig. 3C). Again similarly to wild-type mice, 
heparin did not affect the liver association of the core remnants in lrp-ldlr-/-vldlr-/- mice, as
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Figure 3  Effect of heparin on the organ distribution of VLDL-like emulsion particles. 
Wild-type mice (A, B) and lrp-ldlr-/-vldlr-/- mice (C, D) were anaesthetized and injected with 500 U/
kg heparin (closed bars) or vehicle (open bars). After 10 min, mice were injected with [3H]TO and [14C]
CO double-labeled emulsion particles (1 mg TG). At t=30 min the animals were sacrificed and tissues 
collected. Tissues were dissolved in Solvable (o/n at 60°C) and measured for 3H-activity (A, C) and 
14C-activity (B, D), corrected for serum radioactivity. Asterisks indicate a statistically significant 
difference (*P<0.05).
judged from an effective liver association of [14C]CO both in the absence (44.3±3.5% of ID/g) 
and presence (42.6±5.0% ID/g) of heparin (Fig. 3D). Since heparin releases LPL and HL 
from endothelial surfaces and the liver, the effective liver association of particle core rem-
nants in lrp-ldlr-/-vldlr-/- mice apparently does not depend on the bridging function of LPL 
and HL.








Association of VLDL-like emulsion particles with hepatocytes from lrp-ldlr-/-vldlr-/- mice is followed 
by slow internalization
We have previously shown that the hepatic binding and uptake of TG-rich lipoproteins and 
VLDL-like emulsion particles is mainly exerted by hepatocytes (29). To establish whether 
binding of VLDL-like emulsion particles to hepatocytes that lack the LDLr, LRP, and VLDLr, 
can still lead to internalization, we incubated freshly isolated hepatocytes with DiI-labeled 
emulsion particles (Fig. 4). These emulsion particles avidly bound to the cell surface upon 
incubation at 4°C. LDLr- and LRP-independent internalization of cell-bound emulsion par-
ticles was observed on further incubation at 37°C, as evidenced by the detection of fluores-
cence in compartments below the cell surface after 30 min of incubation (Fig. 4A). However, 
the rate of internalization was slower as compared to that of wild-type hepatocytes, which 
internalized the majority of cell-associated particles within the same time period (Fig. 4B).
Figure 4  Effect of LRP and (V)LDL receptor-deficiency on the uptake of VLDL-like emulsion particles by hepatocytes. 
Freshly isolated hepatocytes from lrp-ldlr-/-vldlr-/- mice (A) and wild-type mice (B) were incubated (2 h 
at 4°C) in DMEM+2% BSA with 50 nm sized DiI-labeled emulsion particles (100 µg TG/mL). The cells were 
washed to remove unbound particles and further incubated at 37°C. After 30 min, localization of DiI was 
determined by confocal laser scanning microscopy. Intracellular fluorescently labeled compartments 
are indicated by arrows. Under the applied conditions, autofluorescence was negligible.
Association of VLDL-like emulsion particles with hepatocytes from lrp-ldlr-/-vldlr-/- mice involves HSPG-
bound ligands and SR-BI
Since both cell surface HSPG (15) and SR-BI (18) have recently been implicated in the hepatic 
uptake of VLDL, we examined their contribution to the association of [3H]COEth-labeled 
VLDL-like emulsion particles with freshly isolated hepatocytes from wild-type mice versus 
lrp-ldlr-/-vldlr-/- mice after incubation for 3 h at 37°C. Deficiency for the LRP, LDLr and VLDLr 
did upregulate SR-BI expression to some extent, since the association of [3H]COEth-HDL 
with hepatocytes from lrp-ldlr-/-vldlr-/- mice was higher than with hepatocytes from wild-type 
mice (+26%; P<0.05) (Fig. 5). The established SR-BI inhibitor oxLDL (30) inhibited the associa-
tion of HDL with both cell types (approx. -60%; P<0.001).
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Figure 5  Effect of LRP and (V)LDL receptor-deficiency on the association of HDL with hepatocytes. 
Freshly isolated hepatocytes from wild-type mice (left) and lrp-ldlr-/-vldlr-/- mice (right) were 
incubated (3 h at 37°C) in DMEM+2% BSA with [3H]COEth-labeled HDL (20 µg of protein/mL) in absence 
or presence of oxLDL (100 µg protein/mL). The cells were washed to remove unbound particles and 
the cell association of [3H]COEth was measured as dpm/mg cell protein. Values are means ± SD (n=3). 
Asterisks indicate a statistically significant difference (*P<0.05; ***P<0.001).
Remarkably, the cell association of [3H]COEth-emulsion particles was unaffected by defi-
ciency for the LRP, LDLr and the VLDLr (Fig. 6), confirming the contribution of pathways 
other than these classical apoE-receptors to the association of emulsion particles with 
hepatocytes. Heparin, at a concentration of 1000 U/mL that releases all heparin-binding 
proteins from cell surface HSPG including apolipoproteins from cell receptors (13), strongly 
inhibited the cell association (>95%). Also, oxLDL effectively inhibited the association of [3H]
COEth-emulsion particles with wild-type (-60%) and lrp-ldlr-/-vldlr-/- hepatocytes (-78%) to 
a similar extent as [3H]COEth-HDL (approx. 60%), indicating the involvement of SR-BI in 
the cell association of emulsion particles. To evaluate the effect of the bridging function of 
LPL and apoE, we also determined the cell association of emulsion particles after previous 
enrichment with heat-inactivated LPL and apoE. Both LPL and apoE reduced the association 
of emulsion particles with wild-type and lrp-ldlr-/-vldlr-/- hepatocytes. However, both heparin 
and oxLDL still inhibited the association of these LPL- and apoE-containing emulsion parti-
cles with both types of hepatocytes (Fig. 6).







































































































































































































































































































































































































































Figure 6  Effect of LRP and (V)LDL receptor-deficiency on the association of VLDL-like emulsion particles with 
hepatocytes. 
Freshly isolated hepatocytes from wild-type mice (A) and lrp-ldlr-/-vldlr-/- mice (B) were incubated (3 
h at 37°C) in DMEM+2% BSA with 50 nm sized [3H]COEth-labeled emulsion particles (100 µg TG/mL), 
without or with previous enrichment (30 min at 37°C) with heat-inactivated LPL (1 µg/mL) or human 
apoE (6 µg/mL), in absence or presence of heparin (1000 U/mL) or oxLDL (100 µg protein/mL). The cells 
were washed to remove unbound particles and the association of [3H]COEth was measured as dpm/
mg cell protein. Values are means ± SD (n=3). Asterisks indicate a statistically significant difference 
(*P<0.05; **P<0.01; ***P<0.001).
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Discussion
The aim of the current study was to investigate the role of LPL activity in the classical apoE-
receptor-independent clearance of lipoprotein remnants, by modulating LPL activity in lrp-
ldlr-/-vldlr-/- mice, and to determine the mechanisms involved in their hepatic uptake. We 
demonstrate that the hepatic uptake of VLDL core remnants independent of these three 
main apoE-recognizing receptors is positively regulated by LPL activity, and involves HSPG 
and SR-BI.
How could modulation of LPL activity affect the hepatic uptake of lipoprotein remnants in 
absence of the LDLr, hepatic LRP, and VLDLr? In vitro studies have shown that LPL via its 
bridging function can mediate the binding and uptake of lipoproteins and their remnants via 
HSPG (31-34), LRP (35), and the LDLr (34, 36). A function of catalytically inactive LPL in the hepatic 
lipoprotein uptake has also been demonstrated in vivo (37, 38). Likewise, HL has been demon-
strated to participate in the cell binding and uptake of remnant lipoproteins in vitro (39, 40) and 
mediate the clearance of remnant lipoproteins from plasma by its non-lipolytic bridging 
function in vivo (41). However, heparin, which effectively releases LPL and HL from cellular 
binding sites and results in increased lipolysis by enhancing the interaction of the catalyti-
cally active lipases with lipoproteins, did not abrogate the rapid binding of VLDL-like emul-
sion-associated [14C]CO activity with the liver in either wild-type and lrp-ldlr-/-vldlr-/- mice. 
Furthermore, the in vitro studies with isolated hepatocytes showed that enrichment of VLDL-
like emulsion particles with catalytically inactive LPL decreased rather than increased the 
cell association of the particles. These data indicate that the rapid initial hepatic associa-
tion of the particle core remnants in lrp-ldlr-/-vldlr-/- mice is likely to be independent of the 
bridging function of LPL and HL. This conclusion is corroborated by our observation that 
AdAPOC1 reduced the hepatic association of the particle core remnants without affecting 
either post-heparin plasma levels of LPL activity (11.5±7.6 vs 11.4±1.6 µmol FFA/h/mL) or 
LPL protein (295±40 vs 254±53 ng/mL) as compared to AdLacZ. Taken together, the positive 
correlation between plasma LPL activity and hepatic VLDL remnant uptake in lrp-ldlr-/-vldlr-/- 
mice does not seem to be caused by the bridging functions of LPL and HL. Most likely, it is a 
consequence of the catalytic function of LPL, which accelerates the generation of VLDL core 
remnants that subsequently become associated with the liver via mechanisms unrelated to 
the classical apoE receptors and lipases.
So what mechanisms do underlie the binding and uptake of VLDL remnants by the liver 
through apparently non-classical pathways? Although it has been suggested that LRP5 (42), 
apoB-48 receptor (43) and LR11 (44) may play a role in the metabolism of apoB-containing lipo-
proteins, the most likely candidates appear to be HSPG (15) and SR-BI (16, 18).
It has previously been shown that lactoferrin inhibits the binding of chylomicron remnants 
and ß-VLDL to HSPG in vitro (45), since lactoferrin effectively binds to HSPG probably due to its 
structural homology with the heparin binding site of apoE and its overall positive charge (46). 
In addition, lactoferrin reduces the hepatic association of the presently applied VLDL-like 








emulsion particles by 90% in vivo (25), indicating that hepatic association of these particles is 
dependent on HSPG. Protamine, like lactoferrin, binds to HSPG by electrostatic interaction, 
thereby reducing remnant binding (47). We have shown that protamine administration to mice 
that lack both the LDLr and hepatic LRP completely inhibited the liver association of the 
emulsion particles (unpublished observations by P.C.N.R.). These observations thus under-
score the involvement of HSPG in the hepatic association of VLDL-like emulsion particle 
remnants. Indeed, treatment of hepatocytes from wild-type mice and lrp-ldlr-/-vldlr-/- mice 
with heparin at a concentration that releases a number of ligands from cell surface HSPG 
including apolipoproteins from cell receptors (48, 49), strongly inhibited the cell association 
(>95%). This indicates the involvement of HSPG-bound ligands in the binding and possibly 
also uptake of VLDL-like emulsion particles by hepatocytes.
Our observation that heparin did not reduce the liver association of the VLDL-like particle 
core remnants in wild-type and lrp-ldlr-/-vldlr-/- mice is in accordance with previous observa-
tions in ldlr-/- mice (50). The seeming discrepancy that heparin blocks the association of emul-
sion particles with hepatocytes in vitro, but not with the liver in vivo, is probably related to the 
additional effect of heparin in vivo (i.e. accelerated remnant formation through increasing 
plasma LPL activity) as well as to the difference between the doses of heparin used in the 
in vitro and in vivo studies. Al-Haideri et al. (13) have shown that a high concentration of 1000 
U/mL releases all heparin-binding proteins from cells, thereby blocking the association 
of similar emulsion particles to fibroblasts, whereas a low concentration of 10 U/mL only 
displaces a number of ligands from HSPG and had no effect on uptake of emulsion parti-
cles by fibroblasts. Accordingly, we observed that 1000 U/mL heparin blocked association 
of emulsion particles with hepatocytes in vitro, and the generally applied dosage of 500 U/
kg heparin (which corresponds to 10-15 U/mL plasma) did not reduce the liver binding of 
emulsion particles in vivo. Taken together with the fact that heparin at a concentration of 
100 U/mL only marginally affects the binding of newly secreted apoE to cells (5) and does not 
release apoE from immobilized HSPG (51), it is well possible that under the in vivo conditions 
hepatocytes still contain sufficient apoE on the cell surface to allow sequestration of rem-
nants on the hepatocyte surface, and to facilitate remnant uptake via its secretion-capture 
role (5). In addition, it has been shown that the VLDL-like emulsion particles that we used in 
this study rapidly acquire apoE from plasma (25, 52), which would allow plasma-derived apoE 
to also play a role in the subsequent uptake of emulsion particles by hepatocytes.
SR-BI has recently been identified as a receptor that internalizes VLDL holoparticles (18). Our 
in vitro data showed that SR-BI expression by hepatocytes was functionally upregulated to 
some extent by the deficiency for the LDLr, LRP and VLDLr. The established SR-BI inhibi-
tor oxLDL (30) markedly reduced the association of [3H]COEth-labeled VLDL-like emulsion 
particles with hepatocytes from both wild-type and lrp-ldlr-/-vldlr-/- mice to a similar extent 
as that of [3H]COEth-labeled HDL, which indeed indicates the involvement of SR-BI in the 
binding and uptake of VLDL-like emulsion particles by hepatocytes. SR-BI recognizes an 
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array of ligands, including apolipoproteins and negatively charged phospholipids. Since the 
phospholipid surface of the emulsion particles has a negligible charge, as evident from a 
low electrophoretic mobility on agarose gel as compared to (oxidized) lipoproteins (25), it is 
unlikely that SR-BI directly binds to the emulsion-associated phospholipids. Instead, the 
association of VLDL core remnants with hepatocytes through SR-BI most likely involves 
apoE. Mice deficient for the LDLr have elevated plasma apoE levels as compared to wild-
type mice, which are maintained upon the deletion of LRP (3, 53) and the VLDLr (12), and apoE is 
a well-established ligand for SR-BI (54-56).
In conclusion, we have demonstrated that in the absence of the three major apoE-recogniz-
ing receptors, the uptake of VLDL remnants by the liver is regulated by the catalytic function 
of LPL in plasma and involves both hepatic HSPG and SR-BI.
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Objective – In vitro studies implicate that the low-density lipoprotein receptor (LDLR)-related 
protein (LRP) in macrophages has a pro-atherogenic potential. In the present study, we 
investigated the in vivo role of macrophage specific LRP in atherogenesis independent of its 
role in the uptake of lipoproteins.
Methods and Results – We generated macrophage specific LRP deficient mice on an ApoE/
LDLR double deficient background. Macrophage LRP deletion did not affect plasma choles-
terol and triglyceride levels, lipoprotein distribution, and blood monocyte counts. Never-
theless, macrophage LRP deficiency resulted in a 1.8-fold increase in total atherosclerotic 
lesion area in the aortic root of 18-week old mice. Moreover, LRP deficiency also resulted in 
a relatively higher number of advanced lesions. Whereas macrophage and smooth muscle 
cell content did not differ between LRP deficient mice and control littermates, a 1.7-fold 
increase in collagen content and 2.3-fold decrease in relative number of CD3+ T cells were 
observed in lesions from macrophage specific LRP deficient mice.
Conclusions – Our data demonstrate that, independent of its role in lipoprotein uptake, 
absence of LRP in macrophages resulted in more advanced atherosclerosis and in lesions 
that contained more collagen and less CD3+ T cells. In contrast to previous in vitro studies, 
we conclude that macrophage LRP has an atheroprotective potential and may modulate the 
extracellular matrix in the atherosclerotic lesions.
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Introduction
Cardiovascular diseases are the leading cause of morbidity and mortality in the Western World. 
The primary cause of cardiovascular diseases is atherosclerosis, which is characterised by 
lipid accumulation and inflammation in the vascular wall.1,2 Macrophages play a central role 
in the pathogenesis of atherosclerosis by internalising modified low-density lipoprotein (LDL), 
production of cytokines and growth factors, and thus stimulate migration and proliferation of 
smooth muscle cells (SMCs), and plaque development and progression.1
The LDL receptor (LDLR)-related protein (LRP) is a large cell-surface multi-ligand endocytic 
clearance and signalling receptor of the LDLR gene family.3-8 LRP is known to recognise >50 
structurally and functionally different ligands.9,10 It is expressed in a variety of cell types 
including hepatocytes, SMCs, and macrophages.11 The hepatic LRP was originally identified 
as an endocytic receptor for apolipoprotein E (apoE)-rich lipoproteins.4 Recently, we showed 
that hepatic LRP deficiency in mice increased atherosclerosis independent of plasma lipo-
proteins.12 Similarly, SMC specific LRP deficient mice display impaired vessel wall integrity 
and have increased susceptibility to cholesterol-diet induced atherosclerosis.7 These data 
show that LRP protects against the development of atherosclerosis at the level of the liver 
and the SMC, independent of its role in the removal of plasma lipoproteins.
In contrast, several lines of in vitro evidence show that LRP in macrophages has pro-athero-
genic properties. First, LRP is highly expressed in atherosclerotic lesions and upregulated 
in macrophages undergoing foam cell formation.13,14 Second, LRP regulates β2-integrin-
mediated adhesion of monocytes to endothelial cells,15 allowing monocytes to migrate into 
the intima and to differentiate into macrophages. Third, macrophage LRP has also been 
demonstrated to play a role in the translocation of 12/15-lipoxygenase, which stimulates 
the formation of oxidised LDL.16,17 Finally, in concert with the LDLR, LRP can mediate the 
uptake of apoE-rich atherogenic lipoproteins into the macrophage.18-20 Because all these 
processes promote the formation of foam cells, one would predict that LRP promotes the 
development of atherosclerosis at the level of macrophages.
In the present study, we investigated the role of macrophage LRP in the development of 
atherosclerosis in vivo. To this end, macrophage LRP was constitutively deleted in macro-
phages, using the lysozyme M Cre/loxP system.21 Because apoE LDLR double deficient mice 
develop spontaneously human-like atherosclerosis without the necessity of a cholesterol-
rich diet, macrophage LRP was deleted on an apoE22 and LDLR23 double deficient back-
ground. Moreover, this model allowed us to study the role of macrophage LRP independent 
of its classical role in the uptake of lipoproteins via the apoE- and LDLR-mediated path-
way. Our data demonstrate that the absence of macrophage LRP results in more advanced 
atherosclerosis, and in lesions that contain more collagen and less CD3+ T cells. In contrast 
to what in vitro studies would predict, we conclude that, like LRP on hepatocytes and SMCs, 
macrophage LRP has an atheroprotective potential.










Mice with or without Cre recombinase under the lysozyme M promoter (kindly provided by 
I. Förster, University of Munich, Germany) were crossbred with our previously generated 
LRPflox/fox 4apoE-/- 22LDLR-/- 23 to generate mice either with lysozymal M Cre21 (LysMCre+ LRP-
flox/flox apoE-/- LDLR-/- further referred to as mφ LRP-) or without lysozymal M Cre (LRPflox/
flox apoE-/- LDLR-/- further referred to as mφ LRP+).12 Mice were genotyped by polymerase 
chain reaction (PCR) for LysMCre, LRPflox/flox, apoE and LDLR status.4,21-23 After two breed-
ing rounds we obtained mice with the LysMCre+ LRPflox/+ apoE-/- LDLR-/- genotype. LRP and 
lysozyme M are both localised on chromosome 10 in mice. Therefore, our third breeding 
(LysMCre+ LRPflox/+ apoE-/- LDLR-/- x LRPflox/flox apoE-/- LDLR-/-) generated only 2 out of 63 (3%) 
mice that were LysMCre+ LRPflox/flox apoE-/- LDLR-/-, instead of 15 out of 63 (25%) as expected 
in case of a Mendelian inheritance. These two mice were subsequently used for generat-
ing LysMCre+ LRPflox/floxapoE-/- LDLR-/- mice in the consecutive breedings. The inheritance 
pattern of the offsprings was Mendelian (19 female mice with the LysMCre+ LRPflox/flox apoE-
/- LDLR-/- genotype vs. 18 female mice with the LRPflox/flox apoE-/- LDLR-/- genotype). Subse-
quently, these mice were used for our experimental breeding yielding more female mice 
with the LRPflox/flox apoE-/- LDLR-/- genotype (n = 31) than the LysMCre+ LRPflox/flox apoE-/- LDLR-
/- genotype (n = 17). A similar pattern was observed for male mice (18 mice with LysMCre+ 
LRPflox/flox apoE-/- LDLR-/- genotype and 24 mice with LRPflox/flox apoE-/- LDLR-/- genotype). Mice 
were fed a SDS standard rodent chow diet (Technilab-BMI, Someren, The Netherlands) and 
water ad libitum. All animal experiments were approved by the institutional committee on 
animal welfare of TNO Quality of Life.
Macrophage LRP deletion
Peritoneal macrophages were obtained from mφ LRP+ and mφ LRP- mice four days after 
intraperitoneal injection of 1 ml thioglycollate broth (3% w/vol, Difco Grayson, GA) by flush-
ing the peritoneum with 10 ml ice-cold phosphate buffered saline (PBS).  Macrophages were 
washed twice with ice-old PBS and subsequently incubated in RPMI 1640 containing 10% 
foetal calf serum and streptomycine/penicilline in 12 cm culture plates at 37oC for 4 hours. 
After 3 washes with warm PBS, macrophages were lysed with 4 ml lysis buffer (0.1 M Tris, 
1 M EDTA, 0.2 M NaCl, 0.002% SDS, pH 8.6) containing 1 mg proteinase K at 55oC for 30 
minutes. DNA was then isolated using the standard phenol/chloroform/iso-amylalcohol 
method.24 The LysMCre/loxP mediated recombination of the conditional LRP allele in the 
macrophages was established by PCR amplification of primer LRP postlox (5’-GTA GTT ATT 
CGG ATC ATC AGC TA-3’, Invitrogen, The Netherlands) and mLRP12 (5’-GGT GTG ACA TAG 
AGT TTT AAA GAG G-3’), yielding a 400-base pair recombination product.4
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Blood sampling and analysis
Blood samples were obtained via tail bleeding. Samples were collected in EDTA-coated 
vials (Sarstedt, Nümbrecht, Germany). Plasma cholesterol levels were measured by a com-
mercially available enzymatic kit (Roche Diagnostics GmbH, Mannheim, Germany). Plasma 
triglyceride levels were measured by a commercially available one-step enzymatic kit that 
detects free and triglyceride-derived glycerol levels (Roche Diagnostics GmbH, Mannheim, 
Germany). Plasma lipoproteins were size-fractionated by fast protein liquid chromatogra-
phy (FPLC) followed by the determination of the cholesterol levels in the individual frac-
tions. Total blood leukocyte (CD45+), T cell (CD3+), B cell (CD19+) and monocyte/granulocyte 
(CD11b+) numbers were determined by fluorescence activated cell sorting (FACS) analysis 
(TruCOUNT, FACSalibur, BD Biosciences, CA), as described previously.25
Atherosclerosis analysis
Female mφ LRP- mice and control mφ LRP+ littermates were sacrificed at 18-week of age 
(n = 17 and n = 31 for mφ LRP- and mφ LRP+, respectively). Heart and aorta were perfused 
with PBS and were subsequently fixed in phosphate-buffered 4% formaldehyde (pH 7.4), 
dehydrated overnight and embedded in paraffin. Hearts were cross-sectioned (5 µm) with 
40-µm intervals throughout the entire aortic root. Sections of the aortic valve area were 
routinely stained with hematoxylin-phloxine-saffran for morphometric analysis and char-
acterisation of the lesions.  For each mouse, 3 lesions at the aortic root were analysed. 
Per mouse, 4 cross-sections were used for quantification of atherosclerotic lesion area.26 
Areas were determined using Leica Qwin image software (EIS, Asbury, NJ). Atherosclerotic 
lesions were classified according to severity (i.e. early, moderate or advanced lesions), as 
described previously.27 The numbers observed in each category were expressed as per-
centage of the total number of lesions observed within one group of mice.27
Lesion composition analysis
Serial sections of the aortic valve area were stained with rabbit anti-mouse macrophage 
antibody (AIA-312040, 1/1500, Accurate Chemical and Scientific, Westbury, NY) and a mono-
clonal mouse anti-smooth muscle cell α-actin antibody (clone 1A4, M-851, 1/1600, DakoCy-
tomation, Belgium), as described previously.12 Serial sections of the aortic valve area were 
stained with goat α-human matrix metalloproteinase-9 (MMP-9) antibody (C-20, Santa Cruz) 
or with rat α-human CD3 (Serotec). Sections were deparaffinised. Endogenous peroxidase 
was quenched with 0.3% H2O2 in 100% methanol, and nonspecific binding was blocked with 
5% BSA in PBS.  Antigen was retrieved by 0.1% trypsin (w/v) in PBS at 37oC for 30 minutes 
prior to MMP-9 staining or heat treatment in 1 mM EDTA, pH 8.0 for 20 minutes prior to CD3 
staining. The primary MMP-9 (1:200) or CD3 antibody (1:1000) in 1% BSA in PBS was incu-
bated o/n at 4oC followed by a 1-hour incubation with biotinylated secondary rabbit anti-goat 
(1:300) or goat α-rat antibody in 1% BSA in PBS. Following incubation with horseradish per-








oxidase labeled avidin-biotin complex (abc/HRP) (DAKO), peroxidase activity was visualised 
using NovaRED (Vector). Sections were counterstained with Mayer’s hematoxylin.
Collagen was stained using Sirius red (Chroma-Gesellschaft, Stuttgart, Germany).  Lesion 
macrophage (AIA-31240–positive area), smooth muscle cell (α-actin-positive area), MMP-9 
and collagen (Sirius red-positive area) areas were quantified using EIS. Number of CD3+ 
cells was counted in 4-cross sections per valve. All analyses were performed double blindly 
without prior knowledge of the genotype.
Statistical analysis
All data are presented as geometric mean with 68% confidence interval (CI), which rep-
resents one standard deviation from the geometric mean if a log-normal distribution is 
assumed. Data are analysed by means of the Mann-Whitney U test (Graphpad Software ver-
sion 4.02, San Diego, CA). Frequency data for lesion classification were compared by means 
of the χ2 test. P < 0.05 was regarded as statistically significant.
Results
General Characteristics of mφ Specific LRP Deficient mice on an apoE-/- and LDLR-/- Background
DNA isolated from peritoneal macrophages from LysMCre+ LRPflox/flox apoE-/- LDLR-/- (mφ 
LRP-) mice and control LRPflox/flox apoE-/- LDLR-/- (mφ LRP+) littermates was subjected to PCR 
analysis to detect the presence of LysMCre/loxP-mediated recombination of LRP (∆LRP). A 
400-bp ∆LRP PCR product of DNA from these isolated peritoneal macrophages was present 
in the mφ LRP- mice (Fig. 1, lane 1 and 2), whereas no PCR product was detected in peri-
toneal macrophages of mφ LRP+ mice (Fig. 1, lane 3 and 4), indicating successful recom-
bination of LRP in macrophages in the mφ LRP- mice only. All mice appeared healthy and 
displayed no signs of abnormalities. Mean body weight, plasma cholesterol and triglyceride 
levels, and plasma lipoprotein distribution were similar between mφ LRP- mice and control 
mφ LRP+ littermates (Table I and Fig. I, online available at http://atvb.ahajournals.org). The 
circulating CD45+ (total blood leukocytes), CD3+ (T cells) and CD19+ (B cells) cells were 
similar between the mφ LRP- mice and control mφ LRP+ littermates (Table 1, online availa-
ble at http://atvb.ahajournals.org). Likewise, the CD11b+ monocyte and CD11b+ granulocyte 
populations were also similar between the mφ LRP- mice and control mφ LRP+ littermates 
(Table 1, online available at http://atvb.ahajournals.org).
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Table I Composition of atherosclerotic lesions
mφ LRP+ mφ LRP-
lesion content
(x 103 µm2)









76.0 (66.3-87.1) 65 (63-67) 146.0 (124.4-171.2)** 65 (62-67)
α-actine 
1A4-positive area 
9.8 (7.19-12.1) 24 (23-26) 17.6 (13.7-22.6) 27 (26-29)
Sirius red-positive 
area 14.8 (11.5-19.0) 20 (17-23) 27.2 (20.8-35.6)* 34 (30-39)**
Macrophage (AIA-31240-positive), SMC (α-actine-positive) and collagen (Sirius red-positive) were expressed as 
absolute area and as percentage of total lesion area. †Since SMC and collagen stainings may overlap, the sum of 
the AIA-31240- and α-active 1A4- Sirius red-positive area may exceed 100%. Data represent geometric mean and 
68% CI. *P < 0.05, **P < 0.005, statistically significant from mφ LRP+ littermates.
Figure 1 LysMCre/loxP-mediated recombination of LRP in thioglycollate-elicited peritoneal macrophages.
Successful LysMCrelox/P-mediated recombination of LRP was detected in isolated peritoneal macrophages 
from mφ LRP- mice (lane 1 and 2). No recombination was detected in peritoneal macrophages from mφ 
LRP+ mice (lane 3 and 4). LysM: lysozymel M, LysMCre: lysozyme M Cre recombinase
Effect of mφ Specific LRP Deficiency on Atherosclerotic Lesion Size
We investigated the role of LRP in macrophages in the development of atherosclerosis on 
an apoE and LDLR double deficient background. The total atherosclerotic lesion area was 
significantly increased in mφ LRP- mice as compared to control mφ LRP+ littermates at 
18-week of age [geometric mean (68% CI): 24.2 (20.8-28.2) x104 µm2 and 11.3 (9.6-13.3) x104 
µm2 for mφ LRP- and mφ LRP+, respectively, P < 0.001, Fig. 2A]. In addition, mφ LRP- mice 
showed a significant increase in lesion severity as compared to control mφ LRP+ litter-
mates (Fig. 2B). Mφ LRP- mice had a significant lower incidence of early lesions (4.0% vs. 
18.7%, P < 0.05), an equal percentage of moderate lesions (18.0% vs. 18.7%) and a significant 
higher incidence of advanced lesions (78.0% vs. 62.7%, P < 0.05) as compared to the control 
mφ LRP+ littermates. These data indicate that LRP deficiency in macrophages results in 
increased atherosclerotic lesions in mice.































































Figure 2 Quantitative assessment of atherosclerosis at 18-week of age
(A) Atherosclerosis lesion area of mφ LRP- mice () and control mφ LRP+ () littermates quantified at the 
level of the aortic root and (B) lesion categorisation of mφ LRP- mice (black bars) and control mφ LRP+ 
littermates (open bars) shown as percentage of the total number of lesions. Line represents geometric 
mean area for each group. Frequency data were compared by means of the χ2 test; *P<0.05, ***P<0.001, 
statistically significant from different control mφ LRP+ littermates.
Effect of mφ Specific LRP Deficiency on Atherosclerotic Lesion Composition
To investigate whether the LRP in the macrophages also affects the composition of the ath-
erosclerotic lesions, we determined the percentage of macrophages (AIA-31240-positive 
area), SMC (α-actin-positive area) and collagen (Sirius red-positive area) content in the 
individual atherosclerotic lesions of 18-week old mφ LRP- mice and control mφ LRP+ lit-
termates. As expected from the increased total lesion area in the mφ LRP- mice, the total 
macrophage and collagen lesion contents were increased in the mφ LRP- mice as compared 
to control mφ LRP+ littermates (Table 1). The total SMC lesion content was also higher in 
the mφ LRP- mice as compared to mφ LRP+ littermates, although this was not statistically 
significant. To analyse the macrophage, SMC and collagen content independent of the total 
lesion area, we corrected the lesion content for the total lesion area at the level of individual 
lesions. The percentages of macrophage and SMC in the lesions were similar between the 
mφ LRP- and control mφ LRP+ littermates (Table 1). However, the mean percentage of col-
lagen in the lesions per mouse was significantly increased in mφ LRP- mice as compared 
to control mφ LRP+ littermates (Table 1, Fig. 3A). Furthermore, the percentage of colla-
gen was also significantly increased in the individual advanced lesion of mφ LRP- mice as 
compared to control mφ LRP+ littermates, indicating that the increased collagen is also 
independent of lesion severity (Fig. 3B). This is clearly illustrated by the representative pho-
tomicrographs of atherosclerotic lesions of mφ LRP+ and mφ LRP- mice (Fig. 3C and 4D). 
Taken together, the relative macrophage and SMC content of mφ LRP- mice do not differ, 
but the atherosclerotic lesions contain higher collagen content as compared to control mφ 
LRP+ littermates.
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Figure 3  Collagen content of atherosclerotic lesions. (A) Percentage collagen (Sirius red-positive) area of mφ LRP- (     ) and mφ LRP+ (     ) littermates 
 quantified at the level of the aortic root. Every dot represents the average of 3 lesions per mouse (B) Percentage collagen (Sirius red-positive) area 
 in individual advanced lesions of mφ LRP- (     ) and mφ LRP+ (     ) littermates quantified at the level of the aortic root. Every dot represents 1 lesion. 
 Lines represent geometric mean area for each group. Representative photomicrographs of size-matched lesion of mφ LRP+ (C) and mφLRP- (D) 
 stained with Sirius red. Dashed lines represent the border of the atherosclerotic lesions. Arrows indicate intensive accumulation of collagen area.  
*P<0.05  **P<0.01, statistically significant from control mφ LRP+ littermates.    
Potential Mechanism Contributing to Increased Collagen Accumulation in Atherosclerotic Lesions of mφ 
Specific LRP deficient mice
Collagen content in the extracellular matrix can be controlled amongst others by the matrix 
metalloproteinase (MMP)/tissue inhibitor metalloproteinase (TIMP) system and interferon-γ 
(INF-γ).28,29 MMP-9 is an important representative of the MMP/TIMP system that may be 
involved in collagen degradation in the extracellular matrix of atherosclerotic lesions. On 
the other hand T cells can produce IFN-γ, a modulator of collagen synthesis. Therefore, we 
explored the MMP-9 content and T cells in the atherosclerotic lesions. The total MMP-9 area 
was significantly increased in the mφ LRP- mice as compared to control LRP+ littermates 
[geometric mean (68% CI): 18.5x103 (14.5-23.8x103) and 11.6x103 (10.0-13.6x103) µm2 for mφ 
LRP- and mφ LRP+ mice, respectively, P < 0.05]. When corrected for the total lesion area 
at the level of individual lesions, the percentage of MMP-9 content was similar in mφ LRP- 
and mφ LRP+ mice [geometric mean (68% CI): 0.21 (0.17-0.25) and 0.29 (0.26-0.32) % for 
mφ LRP- and mφ LRP+ mice, respectively, P =0.12]. The total number of CD3+ T cells in the 
lesions of the mφ LRP- and mφ LRP+ littermates was similar (Fig. 4A). However, the number 
of CD3+ T cells corrected for lesion size was significantly decreased in the mφ LRP- mice as 
compared to the mφ LRP+ littermates (Fig. 4B). Thus, relative MMP-9 content does not dif-
fer between mφ LRP- mice and mφ LRP+ littermates, whereas the relative number of CD3+ 
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Figure 4  D3+ T cell content of atherosclerotic lesions. (A) Total number of CD3+ T cells and (B) percentage of CD3+ T cells in lesions of mφ LRP- (     ) and 
 mφLRP+ (     ) littermates quantified at the level of the aortic root. Every dot represents the average of 3 lesions per mouse. ***P<0.001, statistically 
 significant from control mφLRP+ littermates.
Discussion
LRP has been shown to have a distinct atheroprotective role at the level of the liver and 
SMC.7,12 However, to date, the role of LRP in the macrophages, the key mediators in the 
pathogenesis of atherosclerosis has not been elucidated in vivo. In the present study, we 
investigated the role of LRP in macrophages in the development of atherosclerosis in vivo 
independent of its classical role in the uptake of lipoproteins via the apoE- and LDLR-medi-
ated pathway. We demonstrated that macrophage specific LRP deficiency leads to a sig-
nificant increase in atherosclerosis. In addition, macrophage specific LRP deficient mice 
exhibit an increase in relative collagen content, whereas the macrophage and SMC contents 
of the plaques were not affected. Furthermore, the plaques of the macrophage specific LRP 
deficient mice contain less relative numbers of CD3+ T cells, whereas the MMP-9 content 
was not different. We conclude that, like LRP from the liver and SMCs, macrophage LRP has 
an atheroprotective potential in apoE LDLR double knockout mice.
Our results are in apparent contradiction with previous in vitro studies, showing that mac-
rophage LRP has pro-atherogenic properties. LRP has a well-established role in the apoE-
mediated uptake of remnant lipoproteins and has thereby pro-atherogenenic potentials in the 
macrophages.4,6,30 Furthermore, macrophage LRP is demonstrated to mediate the adhesion 
and migration of leukocytes,15 formation of atherogenic oxidised LDL,16,17 and the clearance of 
Lihui_10.indd   84 19-1-2009   11:50:12
 Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis  85
pro-atherogenic ligands, such as tissue-type plasminogen activator,12,31 and plasminogen acti-
vator inhibitor-1.32 All these processes promote the formation of foam cell in vitro, which point 
to less atherosclerosis in the absence of macrophage LRP. However, we observed increased 
atherosclerosis macrophage specific LRP deficient mice, despite the exclusion of possible 
apoE- and LDLR-mediated uptake of pro-atherogenic remnant lipoproteins (Table 1, Fig. 2). 
The difference between the previous studies15-17 and our current study may be due to the dif-
ferences in the study designs. In vitro isolated macrophage systems were used in the previous 
studies, whereas an in vivo mouse model was used in the present study. In our in vivo model 
LRP exhibits both pro-atherogenic and anti-atherogenic properties. Our results demonstrate 
that the anti-atherogenic properties of LRP in the macrophages dominate the pro-atherogenic 
properties in apoE and LDLR double deficient mice.
The mechanism by which macrophage LRP modulates atherosclerosis is not clear. Firstly, 
since LRP recognises >50 distinct pro-atherogenic and anti-atherogenic ligands, it can be 
postulated that the increased atherosclerosis in macrophage LRP deficient mice might be 
due to accumulation of pro-atherogenic LRP ligands locally in the vascular wall or in the 
plasma. Pro-atherogenic LRP ligands include coagulation factor VIII,33 von Willebrand fac-
tor 34 and tissue type plasminogen activator. 31,35 We have previously shown that disruption 
of the hepatic LRP gene results in increased plasma levels of these LRP ligands. Secondly, 
recent work has implicated LRP in several signal transduction pathways including the regu-
lation of cell migration and the remodelling of the extracellular matrix. In the present study, 
we show that deletion of the LRP gene in macrophages leads to increased collagen content 
of atherosclerotic lesion independent total area, whereas no differences were observed in 
SMC content (Fig. 3, Table 1). The collagen content in the extracellular matrix can be con-
trolled by the MMP/TIMP system and activated T cells.28,29  Whereas we observed no differ-
ences in MMP-9 content in the lesions, the relative number of T cells is significantly lower in 
the atherosclerotic lesions of the macrophage specific LRP deficient mice (Fig. 4).  Possibly, 
the regulation of lesional collagen as modulated by T cells is impaired in the absence of 
LRP in the macrophages. Obviously, further detailed studies are required to gain additional 
insight into the underlying mechanisms how LRP affects T cell number and collagen con-
tent, and their possible interaction.
Our data provide evidence that LRP has an atheroprotective potential in the apoE LDLR 
double knockout mice at the level of macrophages in addition to the previously shown anti-
atherogenic characteristics of LRP in the liver and SMC, and may modulate the extracel-
lular matrix in the atherosclerotic lesions.
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Macrophage Low-density Lipoprotein Receptor-related Protein Deficiency Enhances 
Atherosclerosis in ApoE/LDLR Double Knockout Mice
Table  Body weight, plasma lipid levels and blood leukocytes of 18-weeks old of mφ LRP- mice and mφ 
LRP+ littermates. 
mφ LRP+ mφ LRP-
Body weight (g) 21.1 (20.7-21.4) 20.9 (20.5-21.3)
Plasma cholesterol (mM) 23.2 (22.3-24.2) 21.9 (21.0-22.9)
Plasma triglyceride (mM)# 1.8 (1.7-1.9) 1.6 (1.5-1.8)
CD45+ (106 cells/mL) 13.4 (12.5-14.4) 13.3 (11.9-14.9)
CD19+ (106 cells/mL) 6.8 (6.3-7.4) 6.5 (5.9-7.3)
CD3+ (106 cells/mL) 4.6 (4.1-5.0) 4.1 (3.6-4.7)
CD11b+ monocytes (106 cells/mL) 1.0 (0.9-1.0) 1.0 (0.9-1.1)
CD11b+ granulocytes (106 cells/mL) 1.7 (1.6-1.9) 1.6 (1.5-1.7)
Data represent geometric mean and 68% CI. #Sum of free and triglyceride-derived glycerol.























Figure  Plasma lipoprotein distribution.
Plasma lipoprotein profiles of mφ LRP- mice () and control mφ LRP+ () littermates were size-fractionated by 
FPLC followed by the determination of the individual fractions. Identical lipoprotein distribution is observed 
between mφ LRP- mice and control mφ LRP+ littermates. VLDL: very-low density lipoprotein, LDL: low 
density lipoprotein, HDL: high density lipoprotein.
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To assess the influence of inflammation on circulating endothelial progenitor cells (EPC) 
and haematopoietic stem cells (HSC) in relation to carotid atherosclerosis in non-diabetic 
patients with metabolic syndrome (MS) without manifest cardiovascular disease (CVD). 
Seventy three male non-diabetic patients with MS without manifest CVD were included. A 
threshold of 1.8mg/L was used to define elevated (CRP+) and low (CRP-) CRP levels. Number 
of HSCs and EPC were quantified by fluorescence-activated cell sorter analysis. Cytokine 
and adhesion molecule profiles were assessed. Carotid atherosclerosis and adipose tissue 
distribution was assessed by MRI. Significantly lower number of EPC (40%, p = 0.001) and 
HSC (61%, p = 0.006) were found in CRP+. Patients with atherosclerotic plaques and CRP+ 
had lower HSC (p = 0.005) and EPC (p = 0.07) compared to CRP-. Subcutaneous adipose 
tissue area was higher in CRP+ at the waist and the hip (25%; p = 0.002 and 21%; p = 0.005 
respectively). In a multiple linear regression analysis TNF-α (β:-0.02; SE: 0.009; p = 0.03) 
and waist circumference (β:-0.016; SE: 0.008; p = 0.049) were found as explanatory variables 
for EPC counts; P-selectin (β:-0.007; SE: 0.002: p < 0.001) and TNF-α (β: -0.024; SE: 0.008; 
p = 0.025) for HSCs.
In conclusion, decreased CEPC and HSC numbers were shown to accompany elevated CRP 
levels in non-diabetic patients with MS without manifest cardiovascular disease. This rela-
tion was observed in subjects with atherosclerotic plaques and elevated CRP levels but not 
in the absence of plaques.
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Introduction
Circulating endothelial progenitor cells (EPC) are vasculogenic cell populations present in 
the mononuclear fraction of peripheral blood, which are thought to be derived from heman-
gioblastic cell that reside in the bone marrow. EPC can incorporate into the endothelial 
monolayer, stimulate proliferation of neighbouring endothelial cells and induce the forma-
tion of new blood vessels.1,2 Significantly lower numbers of EPC have been shown in subjects 
with a high risk for cardiovascular disease3 and in subjects with overt cardiovascular dis-
ease4, especially in combination with the metabolic syndrome.5 In addition, EPC may have 
prognostic6 and therapeutic potential.7,8 The relation between EPC and the extent of athero-
sclerotic disease burden is not yet clearly established.
The metabolic syndrome (MS) is associated with increased cardiovascular morbidity and 
mortality9,10. MS and visceral obesity are also associated with increased plasma C-reactive 
protein (CRP) levels11-13. CRP is a marker of the systemic inflammatory state and is shown to 
be associated with endothelial dysfunction14, atherosclerosis15,16, and future cardiovascular 
events17. CRP attenuates EPC survival, differentiation and function in vitro18. Furthermore, 
CRP levels have been related to circulating cytokine levels such as TNFα and IL6 in patients 
with characteristics of the metabolic syndrome. These key inflammatory cytokines have 
previously been linked to endothelial function and the regulation of bone marrow derived 
vasculogenic cells19-21. The influence of systemic inflammation on these cellular markers of 
endothelial dysfunction has not been studied in vivo in patients with the metabolic syndrome. 
We hypothesized that patients with MS and elevated systemic inflammation would have 
decreased EPC counts compared to MS patients with low systemic inflammation. There-
fore, we assessed the influence of systemic inflammation on EPC and HSC counts in rela-
tion to the extent of carotid atherosclerosis in subjects with the metabolic syndrome without 
diabetes or overt cardiovascular disease. In addition, we explored prevailing cytokine and 
adhesion molecule levels. MRI assessments of the carotid artery and adipose tissue distri-
bution were used to obtain measures of obesity and atherosclerotic disease burden.
Methods
Study design & Subjects
We included 73 male subjects above 50 years of age with visceral obesity and the metabolic 
syndrome according to the International Diabetes Federation criteria.22 Exclusion criteria 
were type 2 diabetes mellitus, manifest cardiovascular disease, use of statins or non-ste-
roidal anti-inflammatory drugs, current smoking, familial history of premature cardiovas-
cular disease, severe obesity(BMI>40 kg/m²), and contraindications for MRI. The subjects 
were divided into two groups with varying inflammatory states defined by the previously 








published mean of CRP in male subjects as threshold (i.e. 1.8 mg/L)23. The study complies 
with the Declaration of Helsinki and was approved by the institutional review committee 
and all subjects gave informed consent. HdB was supported by the Dutch Heart Foundation 
(Grant NHS2006B106)
Anthropometric and laboratory assessments
Screening of potential candidates was performed by medical history, anthropometry and 
selected laboratory values. Extensive laboratory assessments were performed in all 
included subjects within two weeks of MRI assessments. These values were used in the sta-
tistical analysis. Blood pressure was assessed using an automatic blood pressure monitor 
(Omron 705IT, Hoofddorp, The Netherlands). Three measurements were averaged for use 
in the analysis. Blood samples were collected after a 12 hour overnight fast for chemical 
and haematological laboratory assessments.  The high sensitive CRP assay was performed 
with the Tina Quant C-reactive protein (latex) high sensitive assay (Roche, Basel, Switzer-
land). Participants with CRP levels above 15mg/L were regarded as having an intercurrent 
infection and were not included in the assessments.  Insulin was determined in heparinised 
plasma using a solid-phase, two-site chemiluminescent immunometric assay carried out 
on an Immulite 2500(DPC, Los Angeles, USA).
Cytokines and adhesion molecules
The serum levels of cytokines and adhesion molecules were measured using a Randox Evi-
dence Investigator and the Cytokine & Growth Factors Biochip Array and Adhesion Mol-
ecules Biochip Array. The cytokine array contains discrete test regions of immobilized 
antibodies specific to IL-1α, IL-1β, Il-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, TNF-α. The adhesion 
molecule array contains antibodies specific to soluble E-, L- and P-selectin, ICAM-1 and 
VCAM-1. The light signal generated from each test region on the Biochip with antibodies 
labelled with Horse Radish Peroxidase is detected using a super cooled charge coupled 
device camera and compared to that from a stored calibration curve. Sample preparation in 
short: the samples were diluted with assay buffer or diluent and applied to a biochip (well). 
The biochip (carrier) was incubated at 37 oC and shaken at 370 rpm at a thermoshaker for 60 
min. After washing the conjugate (HRM labelled antibodies) was added and again incubated 
at 37oC and shaken at 370 rpm at a thermoshaker for 60 min. After washing 250 µl of a 1:1 
mix of luminol and peroxide was added and incubated for 2 minutes. Finally the carrier is 
imaged using an Investigator System conform the manufacturers instruction.
3T Magnetic Resonance Imaging Protocol
Carotid Imaging: Magnetic resonance imaging was performed on a 3T scanner (Philips, 
Achieva, Best, The Netherlands) as previously described and validated24. In short, after per-
forming the preparatory scan sequences, a dual inversion recovery (black-blood), spoiled 
segmented k-space fast gradient echo sequence with spectral selective fat suppression 
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was used to obtain ten contiguous transverse slices covering 2 cm of the carotid bulb and 
the common carotid artery. In all subjects, images were acquired from the left carotid 
artery. Images were analysed using the Vessel MASS software package developed at our 
institution, as described previously25. Atherosclerotic disease burden was assessed by the 
total vessel wall area of the scanned vessel segment (Total VWA). All scans were also visu-
ally scored for the presence of atherosclerotic plaques as follows: 0: no plaques, 1: focal 
asymmetrical vessel wall thickening < 2x the opposite vessel thickness, 2: focal asymmetri-
cal vessel wall thickening ≥ 2x & < 3x the opposite vessel thickness. 3: focal asymmetrical 
vessel wall thickening ≥ 3x the opposite vessel thickness. When more than one plaque was 
present, the largest was used for classification.
Adipose tissue imaging: Subjects were positioned in the magnet in a supine position. The 
body coil was used for obtaining the images. A sagittal single shot gradient echo sequence 
survey scan was used for the imaging of the vertebral column in the lumbar region. Subse-
quently, a second single shot gradient echo sequence in the transversal plane was used for 
obtaining three contiguous slices of 10mm without angulations. The slices were centred at 
the intervertebral disk level between the 4th and 5th lumbar vertebra. The following param-
eters were used for image acquisition:  echo time 3.7 ms (TE), repetition time7.5 (TR), pulse 
angle 45 degrees, and 2 signal averages were performed. The images were obtained with 
3 breath holds of 6 seconds. The field of view was 500mm. A voxel size of 1mm x 1.3mm x 
10mm was obtained. Images were assessed using the MASS software package developed 
at our institution allowing a semi-automated detection of subcutaneous (SAT) and visceral 
adipose tissue (VAT) area.
Enumeration of EPC and HSCs
Enumeration of circulating hematopoietic stem cells (HSCs) and circulating endothelial pro-
genitor cells (EPC) was performed as recently described.26 This method uses Trucount tubes 
that contain a defined number of brightly fluorescent microbeads, permitting the acquisition 
of absolute counts of cells, even at very low numbers. Circulating HSCs are defined as cells 
with low-expression of CD45, positive for CD34, and located in the lympho-gate on a side- 
and forward-scatter plot. This gating strategy was extended by calculating the number of 
CD34+ cells that also express vascular endothelial growth factor receptor-2 (VEGFR-2) to 
define the number of EPC. This strategy avoids inclusion of mature endothelial cells, which 
are also positive for CD34 and VEGFR-2, since they are located outside the lympho-gate.
Statistical analysis
Continuous variables are presented as mean values ± standard error or as medians and inter-
quartile ranges if the assumption of normality was not met. Comparisons between continuous 
variables were performed with independent samples t tests or Mann-Whitney U tests when 
not normally distributed. Correlations were analyzed with bivariate correlation analysis (Pear-








son’s or Spearman’s correlation depending on distribution). Logarithmically transformed 
HSCs and EPC were used to compare the influence of CRP levels in groups with and without 
atherosclerotic plaques and in multiple linear regression analyses. Multiple linear regres-
sion analysis was performed to evaluate the determinants of precursor cell counts.. Variables 
were selected from all determined anthropometric, laboratory, cytokine profiles, and MRI 
determined adipose tissue distribution if the obtained p-value in a univariate linear regres-
sion analysis was lower than 0.1. The selected variables were used in a multiple regression 
analysis with forward selection. Analyses were performed using SPSS version 12.01 (SPSS, 
Chicago, Illinois, USA). All analyses were two-sided, with a level of significance of α=0.05.
Results
Patient characteristics
Of the 73 included participants in the study, 51 subjects had elevated CRP levels (CRP+), and 
22 subjects had low CRP levels (CRP-). Patient characteristics are shown in table 1. There 
were no differences between both groups in age, systolic, and diastolic blood pressures, 
and total cholesterol levels. Subjects with elevated CRP levels had significantly higher waist 
circumferences (p = 0.01), body weight (p = 0.005), HDL cholesterol levels (p = 0.028), and 
LDL cholesterol levels (p = 0.02) in comparison to subjects with low CRP levels.




n = 51 p
Age (years)* 58.9 (1.14) 59.2 (0.68) ns
Waist circumference 
(cm)
103.5 (99.8-106.9) 108 (102-116) 0.01
Body weight (kg) 87.6 (81.9-94.2) 97.1 (87.9-107.3) 0.005
Systolic BP (mmHg)* 151.8 (4.0) 151.1 (2.5) ns
Diastolic BP (mmHg)* 88.5 (1.9) 89.1 (1.1) ns
TC  (mmol/L)* 5.6 (0.2) 5.9 (0.13) ns
HDL (mmol/L) 1.11 (1.02-1.29) 1.31 (1.11-1.54) 0.028
TG (mmol/L) 2.30 (1.49-3.49) 1.68 (1.24-2.13) ns
LDL (mmol/L) 3.32 (2.64-3.75) 3.70 (3.22-4.30) 0.02
FBG (mmol/L) 5.2 (4.7-5.4) 5.1 (4.9-5.7) ns
HbA1c* 4.9 (0.1) 5.1 (0.1) ns
Insulin (mU/L) 8.5 (6.0-12.4) 10.0 (7.0-15.0) ns
HOMA 1.1 (0.7-1.7) 1.4 (0.9-2.0) ns
CRP (mg/L) 0.94 (0.56-1.47) 2.46 (1.59-3.29) 0.000
Framingham* 14.15 (1.34) 13.02 (0.60) ns
CRP- and CRP+ data are presented as median (interquatile range).*Data are presented as mean (SE). BP: blood 
pressure, TC: total cholesterol, HDL: high-density lipoprotein, TG: triglycride, LDL low density lipoprotein, FBG: 
fasting blood glucose, HOMA: HOMA insulin resistance index, CRP: C-reactive protein
Lihui_10.indd   94 19-1-2009   11:50:16
 Decreased EPC in subjects with the metabolic syndrome without overt cardiovascular disease 95
EPC and HSCs (Table 2)
EPC and HSCs were significantly decreased in CRP+ compared to CRP- (Figure 1). Further-
more, the EPC/HSC ratio was observed to be significantly lower in CRP+ in comparison to 





























Figure  EPC (A) and HSC (B) numbers in patients with elevated CRP (CRP ≥ 1.8 mg/L, CRP+) and low LRP (< 1.8 
mg/L, CRP-) levels.
Table 2 Circulating endothelial progenitor cell and haematopoietic stem cell numbers.
CRP- (n = 22) CRP+ (n = 51) p
EPCs (number/µl) 0.81 (0.21-1.43) 0.18 (0.02-0.51) 0.001
HSCs (number/µl) 0.93 (0.66-1.57) 0.59 (0.34-1.04) 0.006
CEPC/HSC ratio 0.90 (0.39-0.95) 0.47 (0.03-0.92) 0.022
Data are presented as median (interquartile range). EPC: circulating endothelial progenitor, HSC: haematopoietic 
stem cells
Cytokine and adhesion molecule profiles (Table 3)
Plasma concentrations of IL-6 and TNFα were significantly higher in CRP+ vs CRP-, 2.4 
pg/ml [1.90-5.40] vs 1.20 pg/ml [0.88-2.28] and 7.80 pg/ml [0-10.30] vs 6.40 pg/ml [0-7.73] 
respectively. Plasma levels of other cytokines and adhesion molecules did not differ signifi-
cantly between the two groups. Significant correlations were observed between EPC and 
IL-6 (r:-0.32, p = 0.007) and TNF-α (r:-0.26, p = 0.029). HSCs correlated significantly with CRP 
(r:-0.27, p = 0.02), IL-6 (r:-0.27, p = 0.02), TNFα (r:-0.26, p = 0.026), ICAM-1 (r:-0.33, p = 0.004) 
and P-selectin (r:0.39, p = 0.001).








Table 3 The cytokine and adhesion molecule profiles
CRP- (n = 20) CRP+  (n = 51) p
IL-1α (pg/ml) 0.50 (0-0.85) 0 (0-0.80) ns
IL-1β (pg/ml) 0.85 (0-1.73) 0 (0-1.8) ns
IL-2 (pg/ml) 0 (0-6.05) 0 (0-9.70) ns
IL-4 (pg/ml) 4.80 (3.18-5.10) 5.2 (4.80-6.50) ns
IL-6 (pg/ml) 1.20 (0.88-2.28) 2.4 (1.90-5.40) 0.01
IL-8 (pg/ml) 9.40 (6.28-11.53) 9.5 (7.20-11.80) ns
IL-10 (pg/ml) 0 (0-0) 0 (0-0) ns
INF-γ (pg/ml) 0 (0-6.18) 0 (0-6.70) ns
TNF-α (pg/ml) 6.40 (0-7.73) 7.80 (0-10.30) 0.024
VCAM-1 (ng/ml) 509.80 (468.15-630.95) 490.40 (415.80-564.90) ns
ICAM-1 (ng/ml) 305.70 (258.48-372.55) 303.10 (274.60-359.00) ns
E-Selectin (ng/ml) 16.50 (12.88-20.55) 16.60 (12.50-20.90) ns
P-Selectin (ng/ml)* 154.01 (8.54) 152.74 (5.66) ns
L-Selectin (ng/ml) 988.25 (892.15-1110.28) 994.50 (901.10-1097.50) ns
Data are presented as median (interquartile range). *Data are presented as mean (SE)
Table 4 MRI assessed atherosclerotic and adipose tissue distribution
CRP- (n = 22) CRP+ (n = 51) p
Total VWA (cm²) 4.40 (3.85-5.46) 4.53 (4.07-5.30) ns
Plaque 0 no. (%) 7 (31.8) 8 (15.7) ns
Plaque 1 no. (%) 8 (36.4) 25 (49.0) ns
Plaque 2 no. (%) 5 (22.7) 12 (23.5) ns
Plaque 3 no. (%) 2 (9.1) 6 (11.8) ns
VAT (cm²) 388.0 (300.6-515.4) 448.9 (348.8-563.8) ns
Waist SAT (cm²) 649.4 (512.3-722.1) 761.1 (671.8-983.8) 0.001
Hip SAT (cm²) 475.8 (391.5-574.4) 582.1 (510.1-707.9) 0.002
Data are presented as median (interquartile range). VWA: vessel wall area, VAT: visceral adipose tissue, SAT: 
subcutaneous adipose tissue
3T MRI assessments (Table 4)
The extent of carotid atherosclerotic disease burden did not significantly differ between the 
two groups. No difference was observed in the number of atherosclerotic plaques between 
CRP+ and CRP-. Subjects with atherosclerotic plaques and elevated CRP levels had statisti-
cally significant lower HSCs [0.59/µl (1.87) vs 1.07/µl (1.91), p = 0.005] and non-significantly 
lower EPC [0.22/µl (4.69) vs 0.55/µl (5.24), p = 0.07] compared to in CRP-.  No difference was 
seen in HSC and EPC counts in subjects without atherosclerotic plaques. Increased depos-
its of subcutaneous adipose tissue were observed in CRP+ both at the waist (p = 0.001) and 
the hip (p = 0.002). Visceral adipose tissue did not vary between the two groups.
Lihui_10.indd   96 19-1-2009   11:50:16
 Decreased EPC in subjects with the metabolic syndrome without overt cardiovascular disease 97
Multiple regression analysis
Multiple linear regression analysis was performed to adjust for possible confounders influ-
encing the observed differences in EPC and HSC counts as described in Methods. For EPC, 
waist circumference, CRP, hip SAT, and TNFα, had p-values <0.1 in the univariate linear 
regression analyses and were used as independent variables in the multiple linear regres-
sion analysis with forward selection. The obtained model consisted of TNFα (β:-0.02; 
SE:0.009; p = 0.03) and waist circumference (β:-0.016; SE:0.008; p = 0.049) as explanatory 
variables. For the multiple linear regression analysis regarding HSC counts, the following 
parameters were used as independent variables: CRP, TNFα, ICAM, and P-Selectin. The 
final model obtained consisted of P-selectin (β:-0.007; SE:0.002; p < 0.001) and TNFα (β:-
0.024; SE:0.008; p = 0.025) as explanatory variables.
Discussion
This study demonstrates that elevated CRP levels are accompanied by decreased counts of 
EPC, HSCs and EPC/HSC ratio in subjects with the metabolic syndrome without diabetes 
and without overt cardiovascular disease. Subjects with atherosclerotic plaque on MRI have 
lower HCS and EPC counts when low grade inflammation is present while this effect was 
not observed in the absence of plaques. Further exploration related the low cell counts to 
prevailing TNFα and p-Selectin concentrations.
Significantly lower EPC counts have previously been demonstrated in subjects with insu-
lin resistance27, and in subjects with high risk for cardiovascular disease28, especially in 
combination with the metabolic syndrome29. We now studied subjects with the metabolic 
syndrome without DM2 or overt cardiovascular disease to test the hypothesis that systemic 
inflammation is the driver of low cell counts in these patients. Low grade systemic inflam-
mation was indeed accompanied by significantly lower EPC and HSC counts in metabolic 
syndrome. This is in line with studies reporting low EPC in other chronic inflammatory dis-
ease states such as rheumatoid arthritis30. The populations compared in our study were 
significantly different in body weight, HDL-c, LDL-c, and CRP levels. To adjust for the possi-
ble effects of adipose tissue, we repeated the analysis after matching CRP- for body weight 
to a subset of CRP+. Metabolic, anthropometric profile and adipose tissue distribution were 
not different between CRP+ versus the CRP-. Also in this sub-analysis we observed signifi-
cantly lower EPC and HSC counts CRP+ (Data not shown).
EPC are thought to be related to the atherosclerotic process.31 Patients with proven coro-
nary artery atherosclerosis have low EPC counts.32 Similarly, low EPC counts have been 
reported in subjects with an increased risk of accelerated progression of atherosclerosis.33 
Furthermore, decreased EPC counts have been described in other conditions known to be 








accompanied by an increased burden of atherosclerosis such as type 2 diabetes mellitus34 
and chronic kidney disease35. The exact relation between EPC and HSCs and atherosclero-
sis is not clearly established. We used carotid artery MRI to assess atherosclerotic burden, 
as previously described.36 No statistically significant difference in atherosclerotic disease 
burden was observed between CRP+ and CRP-. The influence of CRP on HSC and EPC 
counts was also observed in patients with atherosclerotic plaques and not in the absence 
of plaques. We propose that EPC contribute to the maintenance of the structural stability of 
atherosclerotic lesions. Consequently, loss of EPC would result in increased plaque vulner-
ability. Lower EPC counts have been shown to be associated with higher future cardiovascu-
lar events.37 Our study extends these finding by adding the effect of systemic inflammation 
on precursor cell counts. Thus inflammation, precursor cells, plaque vulnerability and 
events could be regarded as mutually dependent, causally linked phenomena.
We explored the intermediate metabolic and inflammatory pathways related to EPC and 
HSCs. TNFα and IL-6 levels were significantly different between the groups with varying 
CRP levels. TNFα and IL-6 also correlated with EPC and HSC counts. In multiple linear 
regression analysis, TNFα and waist circumference significantly determined EPC counts, 
whereas HSC counts were associated with serum P-selectin and TNFα concentrations. The 
role of IL-6 in the multiple linear regression analysis may have been underestimated in our 
study. The study population consisted of viscerally obese subjects only and visceral obesity 
(waist circumference) was shown to play an important role in determining EPC numbers. On 
the other hand, IL-6 is one of the cytokines most strongly related to visceral adiposity. This 
may have confounded the relation between IL6 and EPC counts. The pronounced effect of 
visceral obesity (waist circumference) as explanatory variable for EPC suggests other adi-
pocytokines may affect precursor cell status in addition to IL-6 in these patients. TNFα and 
IL-6 have previously been linked to endothelial function 38,39. TNFα has also been shown to 
inhibit EPC proliferation and differentiation in vitro in a dose dependent manner.40 P-selectin 
contributes to the adhesive surface of activated platelets adhered to inflamed endothelial 
cells or extracellular matrix.41,42  This surface is regarded to serve as the anchor place for 
circulating cells. Our in vivo observations relating cytokines and adhesion molecules to EPC 
and HSC counts are inline with these previous in vitro studies.
Our study has limitations. It was designed as a cross-sectional observational study only 
exploring circulating inflammatory cytokines and adhesion molecules. In addition, no in 
depth differentiation analysis of other bone marrow derived circulating cells was per-
formed. However, our observations point to the relevance of EPC and HSCs in this patient 
category, and show for the first time the significance of low grade inflammation on fate of 
bone marrow derived cells in these patients. Future research may focus on the exact dif-
ferentiation routes in vivo, including the effect of therapeutic manipulation of the systemic 
inflammation by for instance salicylates or thiazolidinediones.
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In conclusion, lower counts of EPC and HSCs were shown to accompany elevated CRP levels 
in subjects with the metabolic syndrome without diabetes or overt cardiovascular disease. 
Interestingly, this was also observed in subjects with atherosclerotic plaques and not in 
the absence of plaques. If EPC are important for the vascular response to injury, systemic 
inflammation may profoundly affect this process.
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Chapter7
General discussion








Overweight and obesity is reaching pandemic proportions and rapidly becoming a major 
health problem in Western societies, momentarily affecting more than 1 billion adults.1The 
pandemic of overweight and obesity is associated with an increased incidence of the meta-
bolic syndrome (MetS). The MetS is now known to be associated with diabetes and increased 
cardiovascular morbidity and mortality.
The research described in this thesis was designed to gain further inside in the different 
aspects of the MetS. The studies were in particular directed to the physiological impact of 
plasminogen activator inhibitor-1 (PAI-1) and the low-density lipoprotein receptor-related 
protein (LRP) with respect to the MetS and atherosclerosis in mouse models. In addition, 
the effect of low-grade inflammation on the endothelial function in human subjects with 
MetS was addressed. The major conclusions and implications of our findings as well as the 
future perspectives will be discussed in this chapter.
PAI-1 catabolism and its role in insulin resistance and obesity
The low-density lipoprotein receptor (LDLR)-related protein (LRP) is a large cell-surface 
multi-ligand endocytic clearance and signalling receptor of the LDLR gene family.2,3 LRP 
was originally identified as an endocytic receptor for apolipoprotein (apoE)-rich lipoproteins. 
LRP is known to recognise >50 structurally and functionally different ligands, including 
plasminogen activator inhibitor-1 (PAI-1).4,5 PAI-1 is the primary inhibitor of the plasmino-
gen activation in vivo. It is not known wether this PAI-1/LRP interaction is of physiological 
importance. Furthermore, it is unknown by what molecular mechanism PAI-1 is cleared 
from the circulation. By using the hepatic LRP deficient mouse model, we studied the role 
of LRP in the clearance of plasma PAI-1 (Chapter 3). We showed that plasma PAI-1 level is 
not regulated by LRP. However, inhibition of the LDLR family by receptor-associated protein 
(RAP) does significantly increase plasma PAI-1 levels.
The LDLR gene family consists of several members. Among them are the LDLR, very low-
density lipoprotein receptor (VLDLR), apolipoprotein E receptor (apoE-R) and megalin. We 
demonstrated that next to LRP both LDLR and VLDLR are also not involved in the regulation 
of plasma PAI-1 levels. Which of the other RAP-sensitive mechanisms regulates plasma 
PAI-1 levels remains to be elucidated. The RAP-sensitive megalin might be good candidate 
for the regulation of plasma PAI-1. Megalin is shown to interact with PAI-1 and mediates 
the endocytosis of PAI-1 for degradation in vitro.6,7 Although PAI-1/LRP interaction does not 
influence plasma levels, the interaction between PAI-1 and LRP might be of importance 
locally at the cellular level. This PAI-1/LRP interaction might be of importance in the clear-
ance of proteins of the haemostasis system, such as thrombin. PAI-1 can promote the clear-
ance of thrombin via LRP.7 Additionally, PAI-1 is a potent chemo-attractant molecule, which 
activity depends on the interaction with LRP for cell signalling.8  Altogether, we propose that 
the interaction between PAI-1 and LRP is of importance on a local level rather than on the 
plasma level.
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In 1986, PAI-1 was firstly described to be linked to insulin resistance.9 Increased plasma 
PAI-1 levels and further progression of the increased plasma PAI-1 levels correlate 
strongly with insulin resistance.10,11 Improvement of insulin resistance by diet or pharmaco-
logic intervention is correlated with decreased plasma PAI-1 levels.12,13 Diet-induced obesity 
and insulin resistance were prevented in PAI-1 deficient mice on a wild-type background.14 
Increased plasma PAI-1 levels are suggested to be the result of increased expression 
of PAI-1 by adipose tissue and ectopic fat depots.10 These studies together generate the 
hypothesis that PAI-1 can cause the development of obesity and insulin resistance. It is not 
known whether attenuated plasma PAI-1 clearance contributes to the increased plasma 
PAI-1 levels observed in insulin resistance. In chapter 2 we demonstrated that increased 
plasma PAI-1 levels in diet-induced insulin resistant obese mice is not due the decreased 
plasma PAI-1 clearance. Moreover, we showed that plasma PAI-1 levels followed obesity 
and insulin resistance in time with delay of weeks suggesting that PAI-1 is not causally 
related to insulin resistance. Several other studies support our data. The study by Morange 
et al showed that PAI-1 deficient mice develop more adipose tissue.15 Transgenic mice over-
expressing PAI-1 have lower body weight, lower adipose tissue mass and less intraperito-
neal fat.16 A new hypothesis might be proposed that the increased PAI-1 levels observed in 
the epidemiological studies and animal studies are an epiphenomenon of inflammation in 
the setting of insulin resistance and obesity.
PAI-1 is an acute phase protein and can be induced by inflammation such as induced by 
lipopolysaccharide injection.17  Obesity and insulin resistance are positively correlated with 
low-grade inflammation. Inhibition of inflammation is demonstrated to decrease plasma 
PAI-1 levels in subjects with insulin resistance.13 The pro-inflammatory marker tumor 
necrosis factor-α (TNF-α) is elevated in obese human subjects and rodents.18 Obese mice 
deficient of TNF-α remain insulin sensitive.19 TNFα is known to induce the expression of PAI-
1.20 Taken altogether, these findings support our hypothesis that increased plasma PAI-1 
levels are an epiphenomenon in the setting of insulin resistance and obesity rather than a 
causal factor. The data from the different PAI-1 deficient mouse models could be explained 
by the different environment/housing or genetically different inflammatory background. 
This epiphenomenon of increased plasma PAI-1 levels in the setting of insulin resistance 
could be of significant clinical importance in regard to cardiovascular events. Subjects with 
insulin resistance have increased cardiovascular risk at the same amount of atheroscle-
rotic burden compared to subjects without insulin resistance. It is apparent that many stud-
ies are still needed to investigate the exact mechanisms underlying the involvement of PAI-1 
in the development of insulin resistance and obesity.








Role of LRP in atherosclerosis
The traditional view of the development of atherosclerosis is the accumulation of choles-
terol in the vessel wall facilitated by elevated plasma cholesterol levels packed in lipopro-
teins. These lipoproteins are processed and hydrolysed during the transport before taken 
up by the liver by the LDLR and LRP or the peripheral tissue by the VLDLR. Alternative 
pathways for the clearance of the triglyceride (TG)-rich lipoproteins are heparin sulphate 
proteoglycans (HSPGs) and the scavenger receptor class B type I (SR-BI).21-23 Lipoprotein 
lipase (LPL) is the key enzyme responsible for the hydrolysis of TG-rich lipoproteins and 
is suggested to play a role in the uptake of the TG-rich lipoproteins by the LDLR and LRP 
in vitro.24  By using the LRP-LDLR-/-VLDLR-/- mouse model (Chapter 4), we demonstrated 
that LPL activity also regulates the hepatic uptake of TG-rich lipoproteins via a pathway dif-
ferent from the lipoprotein receptors pathway. We confirmed that both the HSPG and SR-BI 
pathways are also involved in the clearance of the TG-rich lipoproteins. Therefore plasma 
lipoprotein levels not only depend on the activity of the lipoprotein receptors, but also on 
the activity of LPL and the non specific receptors HSPGs and SR-BI. As a consequence, 
impaired activity of these pathways can result in the development of  hyperlipidemia, and 
eventually atherosclerosis.25,26
Atherosclerosis is also considered as an inflammatory disease of the vascular wall.27 Mac-
rophages play a central role in the pathogenesis of atherosclerosis. Several lines of evidence 
suggest that LRP in the macrophages promotes the development of atherosclerosis, since it 
stimulates foam cell formation.28-35 However, these are all indirect in vitro studies. Therefore, 
we took the advantage of the unique mouse model of macrophage specific LRP deficiency to 
investigate the role of LRP in macrophages in the development of atherosclerosis (Chapter 
5).  We demonstrated that LRP in the macrophages protects against the development of 
atherosclerosis. The mechanism by which macrophage LRP modulates atherosclerosis is 
not clear yet.  A careful control of the balance between the pro-atherogenic and anti-ather-
ogenic LRP ligands is obviously necessary.  As important is a strict regulation of cell migra-
tion and remodelling of the extracellular matrix. Therefore, it can be postulated that the LRP 
in the macrophages plays a central role in both controlling the balance between the pro-
atherogenic and anti-atherogenic ligands,  and the regulation of the extracellular matrix, 
since it is a multi-ligand multifunctional receptor.36-40 This hypothesis is supported by tissue 
specific LRP deficient mouse models. Hepatic LRP deficiency results in increased plasma 
apoE-rich lipoproteins. Additionally, independent of the plasma lipoproteins LRP deficiency 
in the liver and smooth muscle cell (SMC) results in increased atherosclerosis and impaired 
vascular structure.40,41 In the absence of LRP, the accumulation of pro-atherogenic ligands 
was observed and the tight regulation of cell migration and the remodelling of the extracel-
lular matrix obliterated. We demonstrated that LRP deficiency in the macrophage results 
in increased extracellular collagen matrix. Since the extracellular collagen accumulates 
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in the atherosclerotic plaque in the absence of LRP in the macrophage, one can propose 
that LRP deficiency results in a stable plaque. However, the definition of a stable plaque is 
disputable. One could also propose that LRP in the macrophage controls the regulation of 
cell migration and remodelling of the extracellular matrix as LRP in the SMC. The extracel-
lular collagen is tightly controlled amongst others by the matrix metalloproteinase (MMP)/
tissue inhibitor metalloproteinase (TIMP) system and interferon-γ (IFN- γ).42,43 MMP-9 is an 
important representative of the MMP/TIMP system and is a known ligand of LRP.44 The role 
of MMP-9 is not unambiguous. We did not observe increase of MMP-9.  On the other hand, 
extracellular collagen is modulated by T cells via IFN- γ. T cells inhibit the production of the 
extracellular matrix stimulated by INF- γ. We demonstrated that the number of T cells was 
decreased in the atherosclerotic plaques when LRP is absence in the macrophages. One 
could also propose that LRP in the macrophages controls the inflammatory process in the 
development of atherosclerosis. This hypothesis is supported by the observed increased 
inflammatory markers, such as the monocyte chemo-attractant protein type-1 (MCP-1) and 
TNF-α, present in the atherosclerotic plaques in macrophage LRP deficient mice.45 It is also 
suggested that LRP in the macrophage suppresses the inflammation via the NF-κB path-
way.46 All these evidences are in line with the current conception that atherosclerosis is an 
inflammatory disease of the vascular wall.
Role of inflammation in atherosclerosis in subjects with MetS
MetS is associated with chronic low-grade systemic inflammation. More and more evidence 
is accumulating that inflammatory markers are predictive to cardiovascular risks. One of 
the inflammatory markers associated with MetS is the C-reactive protein (CRP).47 CRP is 
shown to be associated with endothelial damage and atherosclerosis.48 Under physiological 
conditions endothelial damage is restored by the circulating endothelial progenitor cells 
(EPC). After incorporation into the endothelial monolayer, the EPC stimulate the prolifera-
tion of the neighbouring endothelial cells restoring the damaged endothelium.49 Circulating 
EPC are thought to be derived from hemangioblastic cells that reside in the bone marrow. 
Lower numbers of circulating EPC are observed in subjects with cardiovascular diseases.50 
We demonstrated that elevated inflammation as measured by CRP levels is associated with 
decreased numbers of circulating EPC in subjects with the MetS (Chapter 6). The pres-
ence of atherosclerotic lesions as assessed by magnetic resonance imaging (MRI) also 
correlates with lower number of EPC. Very interesting is the similar observation in other 
chronic inflammatory diseases such as rheumatoid arthritis.51 Therefore, one can propose 
that lower circulating EPC levels are associated with a chronic inflammatory state. The 
mechanism underlying these observations is not completely clear. Is the increased utilisa-
tion of EPC by the damaged endothelium an explanation for the low number of circulating 
plasma EPC? Or is it the inflammatory state that suppresses the production of EPC? Or is it 
both? We demonstrated that the number hematopoietic stem cells (HSC) is decreased when 








low-grade inflammation is present. We also showed that the lower numbers of EPC and 
HSC are accompanied by higher levels of inflammatory markers like TNF-α and p-selectin. 
Therefore, suppressed production might be an explanatory factor. However, the questions 
remain unsolved since our study was an observational study. To elucidate the underlying 
mechanism, in vitro studies need to be performed on how inflammatory markers can influ-
ence the number or the function of the EPC and HSC.
Concluding remarks
It should be realised that multiple factors are involved in the pathophysiology of the met-
abolic syndrome and its increased risk for cardiovascular diseases.  Although intensive 
research is being performed, much research is still required before therapeutic interven-
tions targeting the metabolic syndrome can be developed.
In this thesis we showed the PAI-1 catabolism is facilitated by a RAP-sensitive mechanism 
other than LRP, LDLR and VLDLR. The increased plasma PAI-1 levels observed in insulin 
resistance and obesity is not explained by impaired clearance of PAI-1. The increased plasma 
PAI-1 levels might be an epiphenomenon of the chronic inflammatory state of insulin resist-
ance or obesity. Furthermore, alternative pathways other than the traditional lipoprotein 
receptors are involved in the regulation of plasma cholesterol and triglyceride levels. The 
development of atherosclerosis is multi-factorial in which the balance between the anti- 
and pro-inflammatory processes plays a central role.  Macrophage LRP might be one of 
the features that control this balance. Inflammation not only promotes to the development 
of atherosclerosis, but might also be involved in the processes that restore the damaged 
vascular wall. Insulin resistance and cardiovascular diseases are becoming epidemic in the 
western world concerning both children and adults. Since increased chronic inflammation 
is particularly fundamental to this, demanding research on this aspect of metabolic syn-
drome is very much needed.
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Summary
The metabolic syndrome is an increasing problem in our Western society. It involves multi-
ple aspects like obesity, insulin resistance, dyslipidemia and low-grade chronic inflamma-
tion. Subsequently, it has a major impact on the development of atherosclerosis, therefore 
cardiovascular diseases. The aim of this thesis was to expand our knowledge of the differ-
ent aspects of the metabolic syndrome at the molecular level, specifically the plasminogen 
activator inhibitor-1 (PAI-1), insulin resistance, low-density lipoprotein receptor-related 
protein (LRP) and atherosclerosis. For this purpose, we used different transgenic mouse 
models and an observational study with human subjects.
Obesity and insulin resistance are key components of the metabolic syndrome. Plasma 
PAI-1 levels are increased in patient with the metabolic syndrome. The increased plasma 
PAI-1 levels are suggested to be the result of increased expression in the vascular endothe-
lium, adipose tissue and liver. However, it is not known if the clearance also contributes to 
the increased plasma PAI-1 levels. Chapter 2 describes the clearance of plasma PAI-1 in a 
genetically and a diet-induced insulin resistant mouse models.  We showed that increased 
plasma PAI-1 levels in diet-induced insulin resistant obese mice are not due to decreased 
plasma PAI-1 clearance. We also demonstrated plasma PAI-1 levels followed obesity and 
insulin resistance in time. These data suggest that PAI-1 is probably not causally involved 
in the development of insulin resistance. Increased PAI-1 levels might merely be an epiphe-
nomenon in the setting of insulin resistance and obesity.
PAI-1 interacts with the low-density lipoprotein receptor (LDLR)-related protein (LRP) in 
vitro. A number of studies have shown that LRP can bind, internalise and degrade PAI-1 in 
vitro. However, it is not known whether LRP indeed plays a role in the clearance of plasma 
PAI-1 in vivo. Chapter 3 addressed the role of hepatic LRP in the regulation of plasma PAI-1 
in vivo. For this purpose, we studied the clearance of PAI-1 in hepatic LRP deficient mice 
under different conditions. We showed that hepatic LRP is not involved in the regulation 
or clearance of plasma PAI-1 levels. Additionally, we demonstrated that receptor-associ-
ated protein (RAP)-sensitive mechanism other than the very low density lipoprotein recep-
tor (VLDLR) or the low density lipoprotein receptor (LDLR) is involved in the regulation of 
plasma PAI-1 levels.
Hepatic LRP deficient mice have elevated fasted plasma cholesterol and triglyceride levels, 
mainly present as VLDL particles on a LDLR-/-VLDL-/- background. Since VLDL is continu-
ously produced in the liver, VLDL remnants still need to be cleared to maintain a steady 
state level. Chapter 4 addressed the whether LPL activity is important for the hepatic clear-
ance of VLDL remnants independent of the three major apoE-recognizing receptors LRP, 
LDLR and VLDLR.  For this purpose, we used mice deficient of LRP, LDLR and VLDLR. We 







demonstrated that the clearance of triglyceride (TG)-rich lipoproteins depends on the LPL 
activity and the non-specific receptors heparin sulfate proteoglycans (HSPG) and scavenger 
receptor BI (SR-BI) in the absence of the three major lipoprotein receptors LDLR, LRP and 
VLDLR.
LRP in the liver and SMC is shown to have atheroprotective role. Macrophages play a key 
role in the development of atherosclerosis next to SMC. Data from several in vitro stud-
ies suggest a pro-atherogenic of LRP in the macrophage. In chapter 5 we investigated the 
role macrophage LRP in the development of atherosclerosis in vivo. We demonstrate that, 
independent of its role in lipoprotein uptake, absence of LRP in macrophages resulted in 
more advanced atherosclerosis and in lesions that contained more collagen and less CD3+ 
T cells. In contrast to previous in vitro studies, we conclude that macrophage LRP has an 
atheroprotective potential and may modulate the extracellular matrix in the atherosclerotic 
lesions.
Patients with the metabolic syndrome have chronic low-grade inflammation and increased 
risk for cardiovascular diseases. Chapter 6 describes the influence of low-grade inflam-
mation on the number of endothelial progenitor cells (EPCs) in patients with the metabolic 
syndrome. EPCs are thought to restore the endothelial layer when damaged. Here we dem-
onstrated that increased low-grade inflammation as reflected by increased C-reactive pro-
tein (CRP) levels is accompanied by decreased numbers of EPCs and hemopoeitic stem 
cells (HSCs) in subjects with the metabolic syndrome. Subjects with atherosclerotic plaques 
have also lower number of EPCs and HSCs as compared to subjects without atherosclerotic 
plaques. Therefore, low-grade inflammation is suggested to affect the vascular damage.
Taken together, the studies in this thesis contribute to understanding of the different molec-
ular aspects of the metabolic syndrome, in particular PAI-1, insulin resistance, LRP and 
atherosclerosis.  However, much further research is still needed to understand the meta-
bolic syndrome and the subsequent cardiovascular diseases.
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Samenvatting
Het metabool syndroom is een toenemend probleem in onze westerse samenleving. Ver-
schillende aspecten zoals vetzucht, insuline resistentie, dyslipidemie and laag gradig chro-
nische ontsteking. Het gevolg hiervan is dat het metabool syndroom grote impact heeft op 
de ontwikkeling van atherosclerose (aderverkalking) en daarmee ook hart- en vaatziekten. 
Het doel van dit proefschrift was de kennis van de verschillende aspecten van het meta-
bool syndroom op het moleculaire niveau te vergroten. In het bijzonder worden de aspecten 
van plasminogeen activator inhibitor-1 (PAI-1), insuline resistentie, low-density lipoprotein 
receptor (LDLR)-related protein (LRP) en atherosclerose bestudeerd. Hiervoor hebben we 
gebruik gemaakt van verschillende transgene muismodellen en een observationele studie 
bij de mensen.
Overgewicht en insuline resistentie zijn de meest belangrijkste componenten van het meta-
bool syndroom. Plasma PAI-1 concentraties zijn verhoogd in patiënten met het metabool 
syndroom. Deze verhoogde plasma PAI-1 concentraties van de plasma PAI-1 concentraties 
wordt beschouwd als het gevolg van toegenomen expressie door het vaatwand, de vet cellen 
en de lever. Het is echter nog niet bekend of de klaring van PAI-1 ook resulteert in ver-
hoogde plasma PAI-1 concentraties. In hoofdstuk 2 wordt de klaring van plasma PAI-1 in 
een genetisch en dieet geïnduceerde insuline resistent muis model bestudeerd.  We hebben 
laten zien dat de toegenomen plasma PAI-1 concentraties in een dieet geïnduceerde insu-
line resistente obese muismodel niet verklaard kan worden door verminderde klaring van 
PAI-1. Daarnaast hebben we ook laten zien dat toename van plasma PAI-1 concentraties 
later ontstaat dan overgewicht en insuline resistentie in de tijd. Deze data suggereren dat 
PAI-1 waarschijnlijk niet causaal betrokken is bij de ontwikkeling van insuline resistentie. 
De waargenomen toegenomen PAI-1 concentraties kan mogelijk enkel een epifenomeen 
zijn in de setting van insulin resistentie en overgewicht.
Uit literatuur van in vitro studies is gebleken dat PAI-1 een interactie aangaat met LRP. Een 
aantal studies hebben laten zien dat LRP PAI-1 kan binden, opnemen en afbreken.  Het is 
echter niet bekend welke rol LRP heeft in de klaring van PAI-1 in vivo.  Hoofdstuk 3 beschrijft 
de rol van de LRP in de lever in de regulatie van plasma PAI-1 in vivo. Hiervoor hebben we 
de klaring van PAI-1 in muizen zonder LRP in verscheidene condities bestudeerd. We heb-
ben laten zien dat LRP in de LRP niet betrokken is bij zowel de regulatie als de klaring 
van plasma PAI-1. Bovendien laten we zien dat de receptor-associated protein (RAP) sen-
sitieve mechanisme  betrokken zijn bij de regulatie van plasma PAI-1. De RAP sensitieve 
 receptoren LDLR en VLDLR zijn hierbij net als LRP niet betrokken.







Muizen met lever LRP deficiëntie hebben een verhoogde nuchter plasma cholesterol en 
triglyceride concentraties. De cholesterol en triglyceride in deze LRP deficiënte muizen zijn 
voornamelijk in VLDL partikels aanwezig op een LDLR-/- en VLDLR-/- achtergrond. Aan-
gezien VLDL partikels continu worden geproduceerd door de lever, moeten de afgebroken 
VLDL deeltjes nog steeds worden geklaard om een steady state niveau te behouden. In 
hoofdstuk 4 wordt de activiteit van lipoprotein lipase (LPL) in de klaring van de afgebroken 
VLDL deeltjes bestudeerd in de afwezigheid van LRP, LDLR en VDLDR, de drie belangrijk-
ste apolipoprotein E herkennende receptoren. Hiervoor hebben we gebruik gemaakt van 
muizen die deficiënt zijn voor LRP, LDLR en VLDLR. We hebben laten zien dat de klaring van 
triglyceride rijke lipoproteines afhankelijk is van de activiteit van LPL en van heparin sulfate 
proteoglycanen (HSPG) en scavenger receptor B1 (SR-BI), de non-specifieke receptoren 
wanneer LRP, LDLR en VLDLR afwezig zijn.
LRP in de lever en in de gladde spiercellen hebben een beschermende rol in de ontwikke-
ling van atherosclerose. Macrofagen spelen naast de gladde spiercellen een centrale rol bij 
de ontwikkeling van atherosclerose. Data van verscheidene in vitro studies suggereren dat 
LRP in de macrofaag juist atherogeen is. In hoofdstuk 5 hebben we de role van LRP in de 
ontwikkeling van atherosclerose in vivo onderzocht.  We hebben laten zien dat de afwezig-
heid van LRP in de macrofagen juist atherosclerose verergert. Hierbij was het lipoproteine 
metabolisme onafhankelijk van LRP. De atherosclerotische plaques bevat meer collagen en 
minder CD3+ T cellen. In tegenstelling tot de in vitro studies, concluderen we dat LRP in de 
macrofagen een beschermende rol heeft in de ontwikkeling van atherosclerose mogelijk 
door het moduleren van de extracellulaire matrix in de atherosclerotische plaques.
Patiënten met het metabool syndroom hebben chronisch laaggradige ontsteking en ver-
hoogde risico op hart- en vaatziekten. Hoofdstuk 6 beschrijft het gevolg van laaggradige 
ontsteking op het aantal endotheliale voorloper cellen (EPC’s) in patiënten met het meta-
bool syndroom. EPC’s herstellen het beschadigde endotheel. In dit hoofdstuk laten we zien 
dat verhoogd laaggradige ontsteking, weerspiegeld door verhoogde C-reactief protein 
(CRP) concentraties, is geassocieerd met verminderd aantal EPC en hemopoetischce stam 
cellen (HSC’s) in mensen met het metabool syndroom. Mensen met atherosclerose hebben 
ook een lager aantal EPC’s en HSC’s in vergelijking met mensen zonder atherosclerose. 
Dit suggereert dat laaggradige ontsteking een invloed heeft op de beschadiging van het 
endotheel.
Concluderend, de studies beschreven in dit proefschrift leiden tot meer het begrip van de 
verschillende aspecten van het metabool syndroom, m.n. PAI-1, insuline resistentie, LRP en 
atherosclerose. Veel onderzoek is echter nog noodzakelijk om het metabool syndroom te 
begrijpen en daarmee haar hart- en vaatziekten.







ApoE-R2 apolipoprotein E receptor 2
CRP  C-reactive protein
CVD cardiovascular diseases
DM II Type II diabetes mellitus
EGF epidermal growth factor
EGIR European Study Group of Insulin Resistance
EPC endothelial progenitor cells
FFA free fatty acids
HL hepatic lipase
ICAM intracellular cell adhesion molecule-1





LDLR low-density lipoprotein receptor
LPL lipoprotein lipase
LRP low-density lipoprotein receptor-related protein
MCP-1 chemoattractant protein-1
M-CSF macrophage colony-stimulating factor
MetS Metabolic syndrome
NCEP ATP III National Cholesterol Education Program Adult Treatment Panel III
NF-κB nuclear factor κB
PAI-1 plasminogen activator inhibitor-1
PDGF platelet-derived growth factor
PDGF-BB platelet-derived growth factor isoform BB
RAP receptor-associated protein
SAA serum amyloid A
TG triglyceride
TNF-α tumor necrosis factor-α
uPA urokinase plasminogen activator
uPAR urokinase plasminogen activator receptor
VCAM-1 vascular cell adhesion molecule-1
VLDL very low-density lipoprotein
VLDLR very low-density lipoprotein receptor
VSMC vascular smooth muscle cells
WHO World Health Organisation
WT wild-type
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